<?xml version="1.0" encoding="UTF-8"?>
<html
        >
<head>
    <link rel="stylesheet" href="../../../notes_js/css/sample.css"/>
    <script src="../../../notes_js/jquery-1.8.3.js"></script>
    <script src="../../../notes_js/jpntext.js"></script>
    <script src="../../../notes_js/rangy-core.js"></script>
    <script src="../../../notes_js/rangy-serializer.js"></script>
    <script src="../../../notes_js/android.selection.js"></script>
    <script src="../../../notes_js/search.js"></script>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"></meta>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1"></meta>
    <title>JAT V45</title>
    <link rel="stylesheet" href="../../css/style.css" type="text/css"></link>
</head>
<body id="content-body" class="green">
<div id="article_header" class="article_header">
    <div id="article_title" class="article_title">Diagnosis and management of adrenal
        insufficiency
    </div>
    <div id="author-group" class="author-group">
        <div id="authors" class="authors">Irina Bancos, MD <sup>a</sup> <sup>b</sup>, Stefanie
            Hahner, MD <sup>c</sup>, Prof Jeremy Tomlinson, PhD <sup>b</sup>, Prof Wiebke Arlt, MD
            <sup>b</sup> <sup>*</sup><a class="ja50-ce-e-address"
                                        href="mailto:w.arlt@bham.ac.uk"><img border="0"
                                                                             src="image/article_email.png"
                                                                             alt="w.arlt@bham.ac.uk"></img></a>
        </div>
        <div id="author_info_ctrl"><a id="image_div_link" href="#"><span id="plusminus">+</span>
            Author Affiliations &amp; Information
        </a></div>
        <div id="author_info" class="author_info">
            <div id="author-affiliation-div">
                <div class="aff" id="aff1"><sup>a</sup> Division of Endocrinology, Metabolism and
                    Nutrition, Mayo Clinic, Rochester, MN, USA
                </div>
                <div class="aff" id="aff2"><sup>b</sup> Centre for Endocrinology, Diabetes, and
                    Metabolism (CEDAM), School of Clinical and Experimental Medicine, University of
                    Birmingham, Birmingham, UK
                </div>
                <div class="aff" id="aff3"><sup>c</sup> Endocrinology and Diabetes Unit, Department
                    of Medicine I, University Hospital Würzburg, Würzburg, Germany
                </div>
            </div>
            <div id="author-correspondence-div"><p class="aff" id="cor1"><sup>*</sup> Correspondence
                to: Prof Wiebke Arlt, Centre for Endocrinology, Diabetes, and Metabolism, School of
                Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, UK
                <i>E-mail address:</i> <a href="mailto:w.arlt@bham.ac.uk">w.arlt@bham.ac.uk</a></p>
            </div>
        </div>
    </div>
    <div id="front-keywords"></div>
</div>
<div id="ja50-ce-abstract" class="ja50-ce-abstract">
    <div id="lv_0001" class="level1">
        <small>Summary</small>
    </div>
    <div class="ja50-ce-abstract-section"><p class="normal">Adrenal insufficiency continues to be a
        challenge for patients, their physicians, and researchers. During the past decade, long-term
        studies have shown increased mortality and morbidity and impaired quality of life in
        patients with adrenal insufficiency. These findings might, at least partially, be due to the
        failure of glucocorticoid replacement therapy to closely resemble physiological diurnal
        secretion of cortisol. The potential effect of newly developed glucocorticoid drugs is a
        focus of research, as are the mechanisms potentially underlying increased morbidity and
        mortality. Adrenal crisis remains a threat to lives, and awareness and preventative measures
        now receive increasing attention. Awareness should be raised in medical teams and patients
        about adrenal insufficiency and management of adrenal crisis to improve clinical
        outcome.</p></div>
</div>
<hr class="hrabstract"></hr>
<div id="id-body" class="journal-body">
    <div id="lv_0002" class="level1"></div>
    <div id="cesec10"></div>
    <div id="lv_0003" class="level2">Introduction</div>
    <p class="indent">Adrenal insufficiency is caused by failure of the adrenal cortex to produce
        cortisol. This failure can result from loss of function of the adrenal glands (ie, primary
        adrenal insufficiency), which is most frequently caused by autoimmune adrenalitis (Addison's
        disease) and inherited disruption of glucocorticoid synthesis by congenital adrenal
        hyperplasia.<a title="ref4" name="back-bib1" onmouseover="this.style.cursor='pointer'"
                       onfocus="this.blur();"
                       onclick="showPopupMulti('bib1');"><sup>1</sup></a><sup>, </sup><a
                title="ref4" name="back-bib2" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib2');"><sup>2</sup></a><sup>, </sup><a title="ref4"
                                                                                  name="back-bib3"
                                                                                  onmouseover="this.style.cursor='pointer'"
                                                                                  onfocus="this.blur();"
                                                                                  onclick="showPopupMulti('bib3');"><sup>3</sup></a><sup>, </sup><a
                title="ref4" name="back-bib4" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib4');"><sup>4</sup></a> Secondary
        adrenal insufficiency is caused by impaired hypothalamic-pituitary regulation of synthesis
        of adrenal cortisol, mostly caused by tumours of the hypothalamic-pituitary region and their
        treatment with surgery or radiotherapy.<a title="References" name="back-bib5"
                                                  onmouseover="this.style.cursor='pointer'"
                                                  onfocus="this.blur();"
                                                  onclick="showPopupMulti('bib5');"><sup>5</sup></a>
        However, long-term exogenous glucocorticoid treatment also invariably causes adrenal
        insufficiency, with potential reversibility after gradual treatment withdrawal.</p>

    <p class="indent">Thomas Addison first described the clinical phenotype of primary adrenal
        insufficiency in 1855;<a title="References" name="back-bib6"
                                 onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                 onclick="showPopupMulti('bib6');"><sup>6</sup></a> a fatal disease
        until corticosteroid replacement became available. 2 years after Edward C Kendall first
        isolated corticosterone in 1936, S Leonard Simpson<a title="References" name="back-bib7"
                                                             onmouseover="this.style.cursor='pointer'"
                                                             onfocus="this.blur();"
                                                             onclick="showPopupMulti('bib7');"><sup>7</sup></a>
        used synthetic deoxycorticosterone acetate in the treatment of Addison's disease with
        success. However, glucocorticoids were widely available only after the synthesis of
        cortisone, transforming the life of patients with rheumatoid arthritis<a title="References"
                                                                                 name="back-bib8"
                                                                                 onmouseover="this.style.cursor='pointer'"
                                                                                 onfocus="this.blur();"
                                                                                 onclick="showPopupMulti('bib8');"><sup>8</sup></a>
        and prompting the award of the Nobel Prize in Physiology or Medicine to Edward C Kendall,
        Philip S Hench, and Tadeus Reichstein in 1950.</p>

    <p class="indent">Despite these achievements, diagnosis of adrenal insufficiency, optimum
        replacement therapy, and negative long-term health outcomes—including those for quality of
        life and mortality—continue to be substantial challenges. In this Review, we update our
        previous review,<a title="References" name="back-bib9"
                           onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                           onclick="showPopupMulti('bib9');"><sup>9</sup></a> focusing on
        controversies and new developments since 1993.</p>

    <div id="cesec20"></div>
    <div id="lv_0004" class="level2">Causes of adrenal insufficiency</div>
    <div id="cesec30"></div>
    <div id="lv_0005" class="level3">Causes of primary adrenal insufficiency</div>
    <p class="indent">In high-income countries, autoimmune-mediated adrenalitis (Addison's disease)
        with subsequent destruction of adrenal tissue is the most common cause of primary adrenal
        insufficiency, accounting for 68—94% of cases.<a title="References" name="back-bib10"
                                                         onmouseover="this.style.cursor='pointer'"
                                                         onfocus="this.blur();"
                                                         onclick="showPopupMulti('bib10');"><sup>10</sup></a>
        It can occur in isolation (30—40% of cases of Addison's disease) or in combination with
        other autoimmune diseases as part of autoimmune polyglandular syndrome type 1 (10—15%) and
        type 2 (50—60%; <a title="" href="#tbl1" name="back-tbl1"
                           class="ja50-ce-cross-ref">table</a>). Autoimmune polyglandular syndromes
        type 1 (or autoimmune polyendocrinopathy with adrenal insufficiency and hypoparathyroidism,
        mucocutaneous candidiasis, and ectodermal dystrophy) is a monogenic disease caused by
        mutations in the autoimmune regulator gene <i>AIRE</i>; several disease susceptibility genes
        have been identified for autoimmune polyglandular syndrome type 2 and isolated Addison's
        disease (<i>CTLA4, PTPN22, MICA</i> 5.1).<a title="References" name="back-bib11"
                                                    onmouseover="this.style.cursor='pointer'"
                                                    onfocus="this.blur();"
                                                    onclick="showPopupMulti('bib11');"><sup>11</sup></a>
        Autoimmune polyglandular syndrome type 2 and isolated Addison's disease are also associated
        with distinct alleles and haplotypes within the major histocompatibility complex HLA
        including DR3-DQ2, DR4-DQ8, DRB1-0301, and DRB1-0404.<a title="ref4" name="back-bib11"
                                                                onmouseover="this.style.cursor='pointer'"
                                                                onfocus="this.blur();"
                                                                onclick="showPopupMulti('bib11');"><sup>11</sup></a><sup>, </sup><a
                title="ref4" name="back-bib12" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib12');"><sup>12</sup></a></p>

    <div class="tblbor" id="tbl1"><p class="caption"><b>Table</b>
         
        <span class="caption">Causes of adrenal insufficiency according to underlying pathogenesis</span>
    </p><a href="image/si1.gif"><p class="img"><img src="image/si1.gif" alt="image"></img></p></a>

        <p class="tbllgd">The most frequent causes of primary adrenal insufficiency are autoimmune
            adrenalitis and congenital adrenal hyperplasia. Secondary adrenal insufficiency is most
            frequently caused by hypothalamic-pituitary tumours and their treatment. For additional
            details and for rarer causes see <a title="" href="#sec1" name="back-sec1"
                                                class="ja50-ce-cross-ref">appendix</a>. For
            drug-associated causes see <a title="" href="#box1" name="back-box1"
                                          class="ja50-ce-cross-ref">panel 1</a>.</p></div>
    <p class="indent">The most frequent monogenic cause of adrenal insufficiency is congenital
        adrenal hyperplasia (<a title="" href="#tbl1" name="back-tbl1" class="ja50-ce-cross-ref">table</a>).
        Congenital adrenal hyperplasia is caused by mutations in enzymes involved in glucocorticoid
        synthesis, most commonly (about 95% of cases) mutations in <i>CYP21A2</i> encoding
        21-hydroxylase, with an incidence in most populations of one in 12 000 people to one in
        15 000 people.</p>

    <p class="indent">Adrenoleukodystrophy is an X-chromosome linked disorder caused by mutations in
        <i>ABCD1</i> (which encodes for a peroxisomal transporter protein), resulting in the
        defective oxidation of very-long-chain fatty acids and their accumulation in various
        tissues, most notably brain and adrenal cortex. Clinically, adrenoleukodystrophy presents
        with very different phenotypes—ie, cerebral adrenoleukodystrophy, with childhood onset and
        rapid progression of neurodegeneration; and adrenomyeloneuropathy, presenting in late
        adolescence and adulthood with spinal and peripheral neuropathy. Adrenal insufficiency can
        precede neurological symptoms or even be the only manifestation; identical mutations might
        result in very variable penetrance and phenotypes within affected families. The <a title=""
                                                                                           href="#tbl1"
                                                                                           name="back-tbl1"
                                                                                           class="ja50-ce-cross-ref">table</a>
        and <a title="" href="#sec1" name="back-sec1" class="ja50-ce-cross-ref">appendix</a>
        summarise other, rarer, causes of primary adrenal insufficiency.</p>

    <div id="cesec40"></div>
    <div id="lv_0006" class="level3">Causes of secondary adrenal insufficiency</div>
    <p class="indent">Any process that destroys healthy pituitary or hypothalamic tissue can lead to
        adrenocorticotropic hormone deficiency and subsequent loss of stimulation of adrenal
        cortisol synthesis. Pituitary adenomas are the most frequent disease process.<a
                title="References" name="back-bib13" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib13');"><sup>13</sup></a> However,
        other hypothalamic-pituitary tumours, such as craniopharyngiomas, meningiomas, and
        intrasellar and suprasellar metastases can also cause secondary adrenal insufficiency. Rarer
        causes include traumatic brain injury and infection and infiltration of the pituitary (<a
                title="" href="#tbl1" name="back-tbl1" class="ja50-ce-cross-ref">table</a>, <a
                title="" href="#sec1" name="back-sec1" class="ja50-ce-cross-ref">appendix</a>). All
        acquired and most inherited causes of secondary adrenal insufficiency can also result in
        loss of function of other hypothalamic-pituitary axes.</p>

    <div id="cesec50"></div>
    <div id="lv_0007" class="level3">Drug-induced adrenal insufficiency</div>
    <p class="indent">Many drugs can result in decreased cortisol synthesis, increased cortisol
        inactivation, or impaired glucocorticoid action (<a title="" href="#box1" name="back-box1"
                                                            class="ja50-ce-cross-ref">panel 1</a>).
        The most common cause of drug-induced adrenal insufficiency is the suppression of the
        hypothalamic-pituitary-adrenal axis by exogenous glucocorticoid doses of 5 mg prednisolone
        equivalent or higher for longer than 4 weeks, irrespective of route of delivery (topical,
        inhaled, oral, or injected). Similarly, successful treatment of endogenous cortisol excess
        in patients with Cushing's syndrome causes adrenal insufficiency. Recovery of the
        hypothalamic-pituitary-adrenal axis can take many months and time to recovery corresponds,
        to some degree, with the preceding period of glucocorticoid excess.<a title="ref4"
                                                                              name="back-bib14"
                                                                              onmouseover="this.style.cursor='pointer'"
                                                                              onfocus="this.blur();"
                                                                              onclick="showPopupMulti('bib14');"><sup>14</sup></a><sup>, </sup><a
                title="ref4" name="back-bib15" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib15');"><sup>15</sup></a> The
        enzyme CYP3A4 is responsible for metabolism of 80% of drugs and xenobiotics, including all
        steroids. CYP3A4 inactivates cortisol to 6β-hydroxycortisol; therefore, CYP3A4 inducers
        result in rapid inactivation of cortisol and to compensate, patients might need increased
        doses of glucocorticoid replacement.<a title="References" name="back-bib16"
                                               onmouseover="this.style.cursor='pointer'"
                                               onfocus="this.blur();"
                                               onclick="showPopupMulti('bib16');"><sup>16</sup></a>
    </p>

    <div class="ja50-ce-textbox" id="box1">
        <div class="ja50-ce-textbox-label">Panel 1</div>
        <div class="ja50-ce-textbox-caption"><p class="normal">Drugs that interfere with adrenal
            function</p></div>
        <div class="ja50-ce-textbox-body1">
            <div id="lv_0008" class="level1"></div>
            <p class="indent1"><strong>Increased metabolism of glucocorticoids</strong></p>

            <p class="indent"><i>Concomitant use reduces corticosteroid concentrations</i></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Inducers of CYP3A4 (resulting in increased inactivation of cortisol by 6β-hydroxylation)—mitotane, phenytoin, rifampicin, troglitazone, phenobarbital</span></span></span>
            </p>

            <p class="indent"><strong>Impaired glucocorticoid action</strong></p>

            <p class="indent"><i>Peripheral glucocorticoid insensitivity</i></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Glucocorticoid receptor antagonist—mifepristone</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Suppression of glucocorticoid-induced gene transcription—chlorpromazine, imipramine</span></span></span>
            </p>

            <p class="indent"><strong>Suppression of hypothalamic-pituitary-adrenal axis</strong>
            </p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Downregulation of endogenous adrenocorticotropic hormone release—chronic exogenous glucocorticoid administration (including topical, inhaled, oral, intra-articular, or parenteral administration), megestrol acetate, medroxyprogesterone acetate, cyproterone acetate, opiates</span></span></span>
            </p>

            <p class="indent"><strong>Inhibition of steroidogenic enzymes involved in cortisol
                production</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Inhibition of mitochondrial (type 1) cytochrome P450 enzymes (CYP11A1, CYP11B1, CYP11B12)—ketoconazole, fluconazole, itraconazole, etomidate, metyrapone, aminoglutethimide</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Inhibition of 3β-HSD2—trilostane</span></span></span>
            </p>

            <p class="indent"><strong>Adrenal haemorrhage</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Anticoagulants—heparin, warfarin</span></span></span>
            </p>

            <p class="indent"><strong>Autoimmune hypophysitis</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Anti-CTLA4 antibody—ipilimumab</span></span></span>
            </p>

            <p class="indent">For additional details and for rarer causes see <a title=""
                                                                                 href="#sec1"
                                                                                 name="back-sec1"
                                                                                 class="ja50-ce-cross-ref">appendix</a>.
            </p></div>
    </div>
    <div id="cesec60"></div>
    <div id="lv_0009" class="level2">Clinical presentation</div>
    <p class="indent">Presenting signs and symptoms of primary adrenal insufficiency are often
        unspecific. This explains the often long delay in diagnosis, which in many patients is only
        established after acute hospitalisation with adrenal crisis.<a title="ref4" name="back-bib4"
                                                                       onmouseover="this.style.cursor='pointer'"
                                                                       onfocus="this.blur();"
                                                                       onclick="showPopupMulti('bib4');"><sup>4</sup></a><sup>, </sup><a
                title="ref4" name="back-bib17" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib17');"><sup>17</sup></a> As
        established by findings from four large series,<a title="ref4" name="back-bib4"
                                                          onmouseover="this.style.cursor='pointer'"
                                                          onfocus="this.blur();"
                                                          onclick="showPopupMulti('bib4');"><sup>4</sup></a><sup>, </sup><a
                title="ref4" name="back-bib11" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib11');"><sup>11</sup></a><sup>, </sup><a title="ref4"
                                                                                    name="back-bib18"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib18');"><sup>18</sup></a><sup>, </sup><a
                title="ref4" name="back-bib19" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib19');"><sup>19</sup></a> signs
        and symptoms comprise fatigue (84—95% of patients), loss of appetite (53—67%), weight loss
        (66—76%), nausea, vomiting, and abdominal pain (49—62%), and muscle and joint pain (36—40%).
        More specific signs and symptoms are skin hyperpigmentation (41—74%; from enhanced
        activation of skin melanocortin 1 receptors [MC1R] by concentrations of high
        adrenocorticotropic hormone), and salt craving (38—64%) and postural hypotension (55—68%)
        due to mineralocorticoid deficiency. Hyponatraemia (70—80%) is the most common abnormality
        on laboratory tests, followed by hyperkalaemia (30—40%) and normochromic anaemia (11—15%).<a
                title="ref4" name="back-bib4" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib4');"><sup>4</sup></a><sup>, </sup><a title="ref4"
                                                                                  name="back-bib10"
                                                                                  onmouseover="this.style.cursor='pointer'"
                                                                                  onfocus="this.blur();"
                                                                                  onclick="showPopupMulti('bib10');"><sup>10</sup></a><sup>, </sup><a
                title="ref4" name="back-bib17" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib17');"><sup>17</sup></a> Family
        history of autoimmune disease is reported by one in three patients,<a title="ref4"
                                                                              name="back-bib20"
                                                                              onmouseover="this.style.cursor='pointer'"
                                                                              onfocus="this.blur();"
                                                                              onclick="showPopupMulti('bib20');"><sup>20</sup></a><sup>, </sup><a
                title="ref4" name="back-bib21" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib21');"><sup>21</sup></a> although
        rarely includes Addison's disease (generally 2%<a title="References" name="back-bib11"
                                                          onmouseover="this.style.cursor='pointer'"
                                                          onfocus="this.blur();"
                                                          onclick="showPopupMulti('bib11');"><sup>11</sup></a>;
        10% in Norwegians<a title="References" name="back-bib4"
                            onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                            onclick="showPopupMulti('bib4');"><sup>4</sup></a>).</p>

    <p class="indent">In secondary adrenal insufficiency, the mineralocorticoid axis is intact;
        thus, postural hypotension and electrolyte abnormalities are less frequent.<a
                title="References" name="back-bib17" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib17');"><sup>17</sup></a> However,
        hyponatraemia can occur due to decreased inhibitory control of vasopressin secretion,<a
                title="References" name="back-bib22" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib22');"><sup>22</sup></a>
        effectively resulting in mild syndrome of inappropriate antidiuretic hormone secretion.
        Hyperpigmentation is absent because of reduced stimulation of skin MC1R by
        adrenocorticotropic hormone, giving the skin an alabaster-like appearance. Other pituitary
        axes might also be compromised, as might vision due to compression of the optic chiasm.</p>

    <div id="cesec70"></div>
    <div id="lv_0010" class="level2">Diagnosis of adrenal insufficiency</div>
    <div id="cesec80"></div>
    <div id="lv_0011" class="level3">Confirmation</div>
    <p class="indent">The adrenocorticotropic hormone stimulation test, also known as the short
        synacthen test or cosyntropin test, is commonly used for the diagnosis of adrenal
        insufficiency and can be done at any time of the day through assessment of serum cortisol at
        baseline and 30 min or 60 min after parenteral administration of 250 μg of
        adrenocorticotropic hormone (fragment 1—24, containing the first 24 of 39 aminoacids). Some
        investigators have used a low-dose adrenocorticotropic hormone test, which uses 1 μg of
        adrenocorticotropic hormone; however, this test is still a supraphysiological stimulus and
        no advantage has been convincingly shown for this test.<a title="References"
                                                                  name="back-bib23"
                                                                  onmouseover="this.style.cursor='pointer'"
                                                                  onfocus="this.blur();"
                                                                  onclick="showPopupMulti('bib23');"><sup>23</sup></a>
        In addition, commercially available adrenocorticotropic hormone ampoules contain 250 μg
        adrenocorticotropic hormone (1—24), rendering a dilution impractical and too inaccurate for
        routine use. Cortisol response to adrenocorticotropic hormone is slightly higher at 60 min
        than at 30 min,<a title="References" name="back-bib18"
                          onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                          onclick="showPopupMulti('bib18');"><sup>18</sup></a> but there are no
        documented advantages in sensitivity and specificity for the use of either timepoint over
        the other. The exact diagnostic cutoffs depend on assay-specific local reference ranges and
        are usually set at 500—550 nmol/L (18—20 μg/dL) after stimulation by adrenocorticotropic
        hormone. Cortisol secretion follows a characteristic diurnal rhythm, rising in the early
        morning hours (0200—0400), peaking in the morning (0600—0900) and then descending to low
        concentrations in the evening and very low concentrations around midnight.<a
                title="References" name="back-bib19" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib19');"><sup>19</sup></a> Random
        morning cortisol concentrations lower than 80 nmol/L (3 μg/dL) are strongly predictive of
        adrenal insufficiency.<a title="References" name="back-bib24"
                                 onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                 onclick="showPopupMulti('bib24');"><sup>24</sup></a> However, to
        safely establish the diagnosis of adrenal insufficiency, an adrenocorticotropic hormone
        stimulation test should always be done. Importantly, diagnostic tests should never delay the
        prompt start of life-saving hydrocortisone treatment in suspected adrenal crisis; formal
        confirmation of diagnosis can be safely carried out after clinical recovery.</p>

    <p class="indent">Measurement of plasma adrenocorticotropic hormone is the first step in the
        differential diagnosis of adrenal insufficiency (<a title="" href="image/gr1.gif"
                                                            name="back-fig1"
                                                            class="ja50-ce-cross-ref">figure</a>).
        In primary adrenal insufficiency, adrenocorticotropic hormone concentrations are usually
        higher than 100 pg/mL (22 pmol/L);<a title="References" name="back-bib25"
                                             onmouseover="this.style.cursor='pointer'"
                                             onfocus="this.blur();"
                                             onclick="showPopupMulti('bib25');"><sup>25</sup></a>
        plasma renin will also be raised, with concomitantly low serum aldosterone. In secondary
        adrenal insufficiency, adrenocorticotropic hormone concentrations will be low or
        inappropriately normal, whereas mineralocorticoid secretion is normal. Serum
        dehydroepiandrosterone sulfate (DHEAS) will be invariably low in patients with primary and
        secondary adrenal insufficiency.</p>

    <div class="imgbor"><a href="image/gr1.gif"><p class="img"><img src="image/gr1.gif" alt="image"
                                                                    id="fig1"></img></p></a>

        <p class="caption"><b>Figure</b> <span class="caption">Diagnostic algorithm for adults with clinical signs and symptoms suggestive of adrenal insufficiency<br/></span><span
                class="caption">Diagnostic measures should never delay the start of hydrocortisone treatment in suspected adrenal crisis. ACTH=adrenocorticotropic hormone. DHEAS=dehydroepiandrosterone.*Autoimmune adrenal insuffiency is still the most likely diagnosis.<br/></span>
        </p></div>
    <p class="indent">In secondary adrenal insufficiency, in which adrenal atrophy is caused by
        insufficient stimulation of endogenous adrenocorticotropic hormone, the adrenocorticotropic
        hormone stimulation test is also generally useful. However, within 4 weeks of a pituitary
        insult or surgery, the adrenal glands are not yet atrophied and thus will still be
        responsive to adrenocorticotropic hormone, which could wrongly indicate an intact
        hypothalamic-pituitary-adrenal axis. Early postoperative morning concentrations of cortisol
        higher than 275 nmol/L (10 μg/dL) are an accurate predictor of a healthy corticotroph
        reserve.<a title="ref4" name="back-bib26" onmouseover="this.style.cursor='pointer'"
                   onfocus="this.blur();"
                   onclick="showPopupMulti('bib26');"><sup>26</sup></a><sup>, </sup><a title="ref4"
                                                                                       name="back-bib27"
                                                                                       onmouseover="this.style.cursor='pointer'"
                                                                                       onfocus="this.blur();"
                                                                                       onclick="showPopupMulti('bib27');"><sup>27</sup></a>
        The long-term predictive value of adrenocorticotropic hormone stimulation test cutoffs of
        510 nmol/L and 550 nmol/L was assessed retrospectively in a large cohort of patients being
        investigated for secondary adrenal insufficiency. Both had a very low incidence of
        false-negative results.<a title="References" name="back-bib28"
                                  onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                  onclick="showPopupMulti('bib28');"><sup>28</sup></a></p>

    <p class="indent">The insulin tolerance test is the gold standard for diagnosis of secondary
        adrenal insufficiency, but the procedure is cumbersome, expensive, and can be unsafe for
        patients with history of seizures or cardiac disease and special care should be taken if the
        test is carried out in children or elderly patients. The need to achieve an adequate
        hypoglycaemia (serum glucose &lt;2·2 mmol/L [&lt;40 mg/dL]) are additional limiting factors.
        Usually, 0·1 units of insulin per kg of bodyweight is used, however, about a third of
        patients need higher concentrations.<a title="References" name="back-bib29"
                                               onmouseover="this.style.cursor='pointer'"
                                               onfocus="this.blur();"
                                               onclick="showPopupMulti('bib29');"><sup>29</sup></a>
        Peak cortisol concentrations lower than 500 nmol/L (18 μg/dL) are considered diagnostic for
        adrenal insufficiency.<a title="References" name="back-bib30"
                                 onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                 onclick="showPopupMulti('bib30');"><sup>30</sup></a></p>

    <div id="cesec90"></div>
    <div id="lv_0012" class="level3">Differential diagnosis and confirmation of disease cause</div>
    <p class="indent">In primary adrenal insufficiency, increased antibody titres against
        21-hydroxylase and adrenal cortex are indicators of autoimmune adrenalitis,<a
                title="References" name="back-bib31" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib31');"><sup>31</sup></a> the most
        frequent cause of disease once congenital adrenal hyperplasia is ruled out. Therefore
        measurement of relevant autoantibodies is the first step in differential diagnosis. If
        neither the family history nor antibody titre results indicate autoimmune pathogenesis, then
        further investigations should be undertaken (<a title="" href="image/gr1.gif"
                                                        name="back-fig1" class="ja50-ce-cross-ref">figure</a>).
        However, even when titres are negative, autoimmune adrenalitis is still the most likely
        underlying cause because many patients become antibody negative when autoimmune destruction
        has been present for some time.</p>

    <p class="indent">Screening for congenital adrenal hyperplasia in adults with adrenal
        insufficiency consists of investigation for serum 17-hydroxyprogesterone at baseline and
        after stimulation with adrenocorticotropic hormone. In patients who are antibody-negative,
        adrenal imaging is helpful and can reveal infiltrative processes, infection, or haemorrhage.
        Bilateral metastases of solid-organ tumours such as cancers of the lung, breast, and kidney
        are associated with an increased risk of adrenal insufficiency;<a title="References"
                                                                          name="back-bib32"
                                                                          onmouseover="this.style.cursor='pointer'"
                                                                          onfocus="this.blur();"
                                                                          onclick="showPopupMulti('bib32');"><sup>32</sup></a>
        therefore, such patients should undergo screening with an adrenocorticotropic hormone
        stimulation test. In men who are antibody-negative, screening for concentrations of plasma
        very-long-chain fatty acids should be carried out to exclude adrenoleukodystrophy, even when
        no neurological signs are present.</p>

    <p class="indent">In secondary adrenal insufficiency, MRI of the hypothalamic-pituitary area
        should be done first. Pituitary incidentalomas are common and unlikely to cause adrenal
        insufficiency unless they are longer than 1 cm; thus pituitary imaging is warranted only
        when plasma concentrations of adrenocorticotropic hormone are low or inappropriately normal
        and when cortisol does not respond appropriately to adrenocorticotropic hormone
        administration. Review of drug history should include recent use of topical and
        intra-articular corticosteroids and over-the-counter supplements.</p>

    <div id="cesec100"></div>
    <div id="lv_0013" class="level3">Special diagnostic situations</div>
    <p class="indent">In patients in adrenal crisis after hospital admission, if acute adrenal
        insufficiency is clinically suspected, hydrocortisone should be given without delay (100 mg
        bolus injection, followed by 200 mg per 24 h either as a continuous infusion or 50 mg every
        6 h) along with intravenous fluid resuscitation. If possible, blood samples for paired
        cortisol and adrenocorticotropic hormone concentration investigation can be drawn
        beforehand, and in haemodynamically stable patients, an adrenocorticotropic hormone
        stimulation test can be done. However, if there is doubt, it is better to treat promptly and
        confirm the diagnosis later, after the patient is better.</p>

    <p class="indent">More than 90% of circulating cortisol is bound to corticosteroid-binding
        globulin and only the remaining free fraction is biologically active.<a title="References"
                                                                                name="back-bib33"
                                                                                onmouseover="this.style.cursor='pointer'"
                                                                                onfocus="this.blur();"
                                                                                onclick="showPopupMulti('bib33');"><sup>33</sup></a>
        Although not advocated routinely, there are special circumstances in which measurement of
        serum free cortisol and corticosteroid-binding globulin might be useful.
        Corticosteroid-binding globulin is decreased during acute illness, in severe liver disease,
        and in patients with rare gene mutations in corticosteroid-binding globulin (<i>SERPINA6</i>).
        Enhanced oestrogen activity (eg, during pregnancy or intake of oral contraceptives)
        substantially increases corticosteroid-binding globulin, resulting in increased total
        cortisol but unchanged free cortisol. Free cortisol is not routinely measured and studies of
        normal reference values in pregnancy have not been done. Data for tests of salivary cortisol
        are too scarce for firm recommendations.<a title="ref4" name="back-bib34"
                                                   onmouseover="this.style.cursor='pointer'"
                                                   onfocus="this.blur();"
                                                   onclick="showPopupMulti('bib34');"><sup>34</sup></a><sup>, </sup><a
                title="ref4" name="back-bib35" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib35');"><sup>35</sup></a></p>

    <p class="indent">In patients taking exogenous steroids, continuing or recent exogenous
        glucocorticoid treatment can complicate the interpretation of results of adrenocorticotropic
        hormone tests. Careful review of treatment history during the past 12 months (including
        topical, inhaled, intranasal, epidural, or intra-articular routes) is essential. A further
        important consideration is the possibility that some synthetic glucocorticoids can
        cross-react with the immunoassays used to measure circulating cortisol in many routine
        biochemistry laboratories.<a title="References" name="back-bib36"
                                     onmouseover="this.style.cursor='pointer'"
                                     onfocus="this.blur();" onclick="showPopupMulti('bib36');"><sup>36</sup></a>
    </p>

    <p class="indent">Assessment of adrenal reserve in patients who are undergoing planned
        withdrawal of chronic exogenous glucocorticoid treatment can be challenging.<a
                title="References" name="back-bib37" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib37');"><sup>37</sup></a>
        Supraphysiological glucocorticoid therapy causes adrenal atrophy that is slowly reversible
        in most people. However, there is large interindividual variability in the degree of
        suppression of the hypothalamic-pituitary-adrenal axis and the time to recovery.<a
                title="References" name="back-bib14" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib14');"><sup>14</sup></a>
        Glucocorticoids should be tapered slowly and if there is no continuing indication for
        glucocorticoid therapy other than adrenal insufficiency then, ideally, long-acting
        glucocorticoids should be switched to hydrocortisone. Assessment of adrenal function can be
        done after hydrocortisone has been temporarily stopped for 24 h before stimulation testing
        with adrenocorticotropic hormone (1—24). Prednisone, prednisolone, and dexamethasone might
        affect results for at least 48—72 h, if not longer; hence, to switch to hydrocortisone
        before comprehensive testing of adrenal reserve is often prudent.</p>

    <p class="indent">All routes of glucocorticoid administration (oral, inhaled, intranasal,
        topical, intra-articular, intramuscular, and intravenous) have been associated with
        suppression of the hypothalamic-pituitary-adrenal axis. This suppression might be present in
        half of patients taking inhaled glucocorticoid treatment,<a title="ref4" name="back-bib38"
                                                                    onmouseover="this.style.cursor='pointer'"
                                                                    onfocus="this.blur();"
                                                                    onclick="showPopupMulti('bib38');"><sup>38</sup></a><sup>, </sup><a
                title="ref4" name="back-bib39" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib39');"><sup>39</sup></a><sup>, </sup><a title="ref4"
                                                                                    name="back-bib40"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib40');"><sup>40</sup></a>
        although the true magnitude of this problem and the clinical outcomes are still largely
        unknown, and data for optimised diagnostic tests are scarce. If signs and symptoms are
        suggestive of adrenal insufficiency, then dynamic assessment of adrenal reserve should be
        done, but routine screening in all patients taking inhaled, topical, or intranasal therapy
        is not recommended. Often, it is not possible to omit glucocorticoid therapy (such as
        inhaled glucorticoids for asthma), even for a short period of time, further complicating
        assessment. A multidisciplinary team approach is important during clarification of whether
        supraphysiological glucocorticoid therapy is still needed or whether glucocorticoids can be
        carefully tapered. Management can be complex and a balance is needed between prevention of
        adrenal crisis and minimisation of glucocorticoid excess.</p>

    <div id="cesec110"></div>
    <div id="lv_0014" class="level2">Long-term replacement therapy</div>
    <div id="cesec120"></div>
    <div id="lv_0015" class="level3">Glucocorticoid replacement</div>
    <p class="indent">Daily physiological production of cortisol is about 5—6 mg/m<sup>2</sup> body
        surface area.<a title="References" name="back-bib41"
                        onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                        onclick="showPopupMulti('bib41');"><sup>41</sup></a> Recommended
        hydrocortisone doses are 15—25 mg, usually given in two to three doses per day, with 50—66%
        given in the morning on awakening.<a title="References" name="back-bib9"
                                             onmouseover="this.style.cursor='pointer'"
                                             onfocus="this.blur();"
                                             onclick="showPopupMulti('bib9');"><sup>9</sup></a> If
        given two times a day, the second dose is usually given 6—8 h after the morning dose. If
        given three times per day, the second dose is given 4—6 h after the early morning dose and
        the third dose 4—6 h after this. Some clinicians recommend weight-adjusted dosing to reduce
        intervals of excess in cortisol concentrations during the day and decreased variability of
        cortisol profiles.<a title="References" name="back-bib42"
                             onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                             onclick="showPopupMulti('bib42');"><sup>42</sup></a> Decisions about
        number of doses are also based on patient preference, differences in daily activity, and
        patient experience.</p>

    <p class="indent">There is no reliable biochemical marker to assess the appropriateness of dose
        in glucocorticoid replacement treatment, and so dose modification is guided by clinical
        judgment and subjective perception of symptoms and signs of glucocorticoid under-replacement
        and over-replacement. The goal is to achieve the best clinical result with the lowest
        possible daily dose of steroid. Cortisol day curves are of little value in routine
        monitoring.<a title="References" name="back-bib43" onmouseover="this.style.cursor='pointer'"
                      onfocus="this.blur();" onclick="showPopupMulti('bib43');"><sup>43</sup></a> In
        our experience, timed measurement of serum cortisol is of value only when malabsorption or
        increased metabolic clearance is suspected. Monitoring of plasma adrenocorticotropic hormone
        is not useful. Urinary 24 h free cortisol excretion shows large interindividual variability
        and comparisons with normal reference ranges are not useful. This is because of the
        pharmacokinetic properties of glucocorticoid preparations, whereby the kidney excretion
        threshold can be quickly overcome after exogenous administration of glucocorticoids.</p>

    <p class="indent">A global survey of more than 1000 patients, mostly with primary adrenal
        insufficiency, showed that hydrocortisone was the most common treatment (75%), followed by
        prednisone or prednisolone (11%), cortisone (6%), and dexamethasone (4%).<a
                title="References" name="back-bib44" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib44');"><sup>44</sup></a>
        Cortisone (1·0 mg hydrocortisone=1·6 mg cortisone acetate) and prednisone (1·0 mg
        hydrocortisone=0·25 mg prednisone) need intrahepatic activation to cortisol and prednisolone
        (1·0 mg hydrocortisone=0·2 mg prednisolone), respectively, by 11β-hydroxysteroid
        dehydrogenase type 1, which might lead to a higher pharmacokinetic variability compared with
        hydrocortisone. The long-lasting synthetic steroids prednisone and dexamethasone (1·0 mg
        hydrocortisone=0·025 mg dexamethasone) have strong anti-inflammatory action and are
        frequently used in chronic inflammatory disorders.</p>

    <p class="indent">In the past few years, progress has been made in the development of steroid
        preparations to provide a more circadian-rhythm-based serum cortisol profile.<a
                title="References" name="back-bib23" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib23');"><sup>23</sup></a> This
        breakthrough was pioneered by studies that showed superior biochemical control and
        indications of improved quality of life in patients with adrenal insufficiency who received
        intravenous and subcutaneous hydrocortisone infusions.<a title="References"
                                                                 name="back-bib45"
                                                                 onmouseover="this.style.cursor='pointer'"
                                                                 onfocus="this.blur();"
                                                                 onclick="showPopupMulti('bib45');"><sup>45</sup></a>
        An approved option for modified-release oral hydrocortisone is DuoCort Pharma (Helsingborg,
        Sweden) which provides long-acting delivery of hydrocortisone. However, this drug does not
        lead to physiological early morning secretion of cortisol. An early rise in morning cortisol
        can be achieved by modified-release and delayed-release glucocorticoid preparations, such as
        prednisone delayed-release and, possibly more physiologically grounded, by the
        modified-release and delayed-release hydrocortisone drug Chronocort (Diurnal, Cardiff, UK),
        which is now in development.<a title="ref4" name="back-bib19"
                                       onmouseover="this.style.cursor='pointer'"
                                       onfocus="this.blur();"
                                       onclick="showPopupMulti('bib19');"><sup>19</sup></a><sup>, </sup><a
                title="ref4" name="back-bib46" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib46');"><sup>46</sup></a> However,
        data from larger clinical trials on the effect of these newer preparations in patients with
        adrenal insufficiency are still needed. We recommend an individualised approach based on
        clinical symptoms and signs, and the patient's circumstances and preferences.</p>

    <div id="cesec130"></div>
    <div id="lv_0016" class="level3">Mineralocorticoid replacement</div>
    <p class="indent">Fludrocortisone (9α-fluorocortisol) is used for mineralocorticoid replacement
        as a one-morning dose of usually 50—300 μg, with a typical starting dose of 100—150 μg.
        Indicators of adequate mineralocorticoid replacement are electrolytes within normal range,
        blood pressure without a substantial postural drop, and plasma renin concentrations and
        activity in the upper-normal range. Hydrocortisone also has mineralocorticoid activity, with
        40 mg of hydrocortisone equivalent to 100 μg of fludrocortisone.<a title="References"
                                                                           name="back-bib25"
                                                                           onmouseover="this.style.cursor='pointer'"
                                                                           onfocus="this.blur();"
                                                                           onclick="showPopupMulti('bib25');"><sup>25</sup></a>
        Thus, changes in hydrocortisone dose can affect fludrocortisone dose requirements.
        Prednisolone has some mineralocorticoid activity, whereas dexamethasone has none.
        Fludrocortisone requirements can be monitored with use of serum sodium and potassium and
        plasma renin, the latter should range in the upper—normal reference range. Salt craving,
        dizziness, and postural hypotension could indicate under-replacement, whereas peripheral
        oedema and new-onset arterial hypertension could indicate over-replacement. Fludrocortisone
        dose should be increased when there is enhanced salt loss through perspiration—eg, due to
        physical activity or a hot climate (<a title="" href="#box2" name="back-box2"
                                               class="ja50-ce-cross-ref">panel 2</a>).</p>

    <div class="ja50-ce-textbox" id="box2">
        <div class="ja50-ce-textbox-label">Panel 2</div>
        <div class="ja50-ce-textbox-caption"><p class="normal">Treatment of patients in special
            situations</p></div>
        <div class="ja50-ce-textbox-body1">
            <div id="lv_0017" class="level1"></div>
            <p class="indent1"><strong>Individuals doing shift work or who have otherwise shifted
                daily routine (adolescents, students)</strong></p>

            <p class="indent">We recommend changing the timing of steroid replacement according to
                the individual schedule (to take the larger dose of hydrocortisone on waking and the
                second dose 6—8 h after the first one).</p>

            <p class="indent"><strong>Individuals who do intensive exercise</strong></p>

            <p class="indent">Small carbohydrate meals should be considered before a session of
                intense exercise,<a title="References" name="back-bib47"
                                    onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                    onclick="showPopupMulti('bib47');"><sup>47</sup></a> but these
                are not mandatory and depend on individual response. Depending on the degree of
                physical activity and thus expected salt losses from sweating, the patient might
                benefit from a small increase in dose of glucocorticoid and mineralocorticoid
                (2·5—5·0 mg hydrocortisone every 3 h during a marathon; in a hot environment,
                increase fludrocortisone dose by 50—100 μg per day to compensate for salt and water
                loss).<a title="References" name="back-bib48"
                         onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                         onclick="showPopupMulti('bib48');"><sup>48</sup></a></p>

            <p class="indent"><strong>Individuals with primary adrenal insufficiency who develop
                hypertension</strong></p>

            <p class="indent">Appropriateness of fludrocortisone dose should be checked. However,
                patients with Addison's disease also can develop essential hypertension. In this
                situation, a slight reduction of fludrocortisone dose can be considered, allowing
                slightly elevated renin concentrations, but mineralocorticoid treatment should not
                be stopped completely and if needed, appropriate antihypertensive treatment should
                be established, preferably using calcium antagonists and α-blockers.
                Angiotensin-converting enzyme inhibitors and angiotensin-1 receptor blockers are
                ineffective because the renin-angiotensin-aldosterone system is already
                disrupted.</p>

            <p class="indent"><strong>Individuals with newly developed type 2 diabetes</strong></p>

            <p class="indent">Consideration should be made of the appropriateness of glucocorticoid
                dose.</p>

            <p class="indent"><strong>Individuals with insulin-dependent diabetes mellitus</strong>
            </p>

            <p class="indent">Longer-acting glucocorticoids might help to achieve better control of
                glucose levels.</p>

            <p class="indent"><strong>Individuals with thyroid disorders</strong></p>

            <p class="indent">Hyperthyroidism increases cortisol clearance, thus thyrotoxic patients
                with adrenal insufficiency need higher doses of hydrocortisone replacement.
                New-onset hyperthyroidism can elicit an adrenal crisis; L-thyroxine replacement
                should be started only after hydrocortisone replacement has already been
                established. Thyroid-stimulating hormone (TSH) concentrations lower than 10 mU/L in
                patients with newly diagnosed Addison's disease might not indicate hypothyroidism
                because physiologically, secretion of thyrotropin-releasing hormone needs inhibitory
                control by cortisol; therefore, TSH concentrations often normalise with
                hydrocortisone replacement alone.</p>

            <p class="indent"><strong>Individuals undergoing dialysis for end-stage renal
                disease</strong></p>

            <p class="indent">Fludrocortisone is no longer needed and can be stopped; it is
                important to plan daily glucocorticoid replacement because substantial amounts of
                the morning glucocorticoid dose might be lost through haemodialysis.</p></div>
    </div>
    <div id="cesec140"></div>
    <div id="lv_0018" class="level3">Adrenal-androgen-precursor replacement</div>
    <p class="indent">In women, androgen production by the adrenal glands is the main source of
        androgens; therefore, in women, adrenal insufficiency is invariably associated with severe
        androgen deficiency. Serum DHEAS concentrations peak between ages 20 years and 30 years,
        followed by a gradual decline<a title="References" name="back-bib49"
                                        onmouseover="this.style.cursor='pointer'"
                                        onfocus="this.blur();"
                                        onclick="showPopupMulti('bib49');"><sup>49</sup></a> that is
        independent of menopause. The adrenal androgen precursor dehydroepiandrosterone (DHEA) is
        activated to sex steroids in many peripheral tissues and the gonads, but also has
        neurosteroidal activity in the brain. In some, but not all, trials, DHEA supplementation in
        adrenal insufficiency was shown to improve overall wellbeing,<a title="ref4"
                                                                        name="back-bib50"
                                                                        onmouseover="this.style.cursor='pointer'"
                                                                        onfocus="this.blur();"
                                                                        onclick="showPopupMulti('bib50');"><sup>50</sup></a><sup>, </sup><a
                title="ref4" name="back-bib51" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib51');"><sup>51</sup></a><sup>, </sup><a title="ref4"
                                                                                    name="back-bib52"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib52');"><sup>52</sup></a><sup>, </sup><a
                title="ref4" name="back-bib53" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib53');"><sup>53</sup></a>
        depression and anxiety scores,<a title="ref4" name="back-bib50"
                                         onmouseover="this.style.cursor='pointer'"
                                         onfocus="this.blur();"
                                         onclick="showPopupMulti('bib50');"><sup>50</sup></a><sup>, </sup><a
                title="ref4" name="back-bib54" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib54');"><sup>54</sup></a> and
        sexual interest and satisfaction ratings.<a title="References" name="back-bib50"
                                                    onmouseover="this.style.cursor='pointer'"
                                                    onfocus="this.blur();"
                                                    onclick="showPopupMulti('bib50');"><sup>50</sup></a>
        The benefit of DHEA replacement is probably larger in premenopausal women than in women
        after menopause.<a title="References" name="back-bib53"
                           onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                           onclick="showPopupMulti('bib53');"><sup>53</sup></a> DHEA replacement
        could be useful particularly for women with adrenal insufficiency who have otherwise optimum
        glucocorticoid and mineralocorticoid replacement but who have low energy levels, impaired
        mood, and decreased or absent libido. Single oral administration of 25—50 mg DHEA usually
        restores circulating androgen concentrations into the normal range. Monitoring comprises
        measurement of serum DHEAS, androstenedione, testosterone, and sex-hormone-binding globulin
        24 h after the previous morning dose, aiming for mid-normal range concentrations. At
        present, studies for long-term outcomes of chronic DHEA supplementation in hypoadrenal women
        have not been done, and data are not likely to be available soon because the steroid is
        widely available over-the-counter and via the internet.</p>

    <p class="indent">Many environmental, physiological, and pathological disorders can affect
        hormone replacement therapy in patients with adrenal insufficiency (<a title="" href="#box2"
                                                                               name="back-box2"
                                                                               class="ja50-ce-cross-ref">panel
            2</a>). Little evidence exists to suggest an optimum approach in these situations and
        the recommendations in the panel are expert opinion.</p>

    <div id="cesec150"></div>
    <div id="lv_0019" class="level2">Regenerating adrenal function</div>
    <p class="indent">Research has focused on novel therapies beyond optimisation of steroid
        replacement therapy, including immunosuppressive treatment in early stage Addison's
        disease<a title="References" name="back-bib55" onmouseover="this.style.cursor='pointer'"
                  onfocus="this.blur();" onclick="showPopupMulti('bib55');"><sup>55</sup></a> and
        attempts to achieve adrenal transplantation.<a title="References" name="back-bib56"
                                                       onmouseover="this.style.cursor='pointer'"
                                                       onfocus="this.blur();"
                                                       onclick="showPopupMulti('bib56');"><sup>56</sup></a>
        In 2014, a proof-of-principle study showed re-emergence of adrenal function after continuous
        adrenocorticotropic hormone stimulation with depot synacthen in two patients with chronic
        Addison's disease but minor residual function.<a title="References" name="back-bib57"
                                                         onmouseover="this.style.cursor='pointer'"
                                                         onfocus="this.blur();"
                                                         onclick="showPopupMulti('bib57');"><sup>57</sup></a>
    </p>

    <div id="cesec160"></div>
    <div id="lv_0020" class="level2">Treatment and prevention of acute adrenal crisis</div>
    <p class="indent">Adrenal crisis is a life-threatening emergency. Therefore, prevention is of
        key importance. The frequency of crisis has been reported as 6—8 for 100 patient-years, with
        about half of patients with Addison's disease reporting at least one previous adrenal
        crisis.<a title="ref4" name="back-bib58" onmouseover="this.style.cursor='pointer'"
                  onfocus="this.blur();"
                  onclick="showPopupMulti('bib58');"><sup>58</sup></a><sup>, </sup><a title="ref4"
                                                                                      name="back-bib59"
                                                                                      onmouseover="this.style.cursor='pointer'"
                                                                                      onfocus="this.blur();"
                                                                                      onclick="showPopupMulti('bib59');"><sup>59</sup></a>
        The most frequent precipitating causes are gastroenteritis and fever (60—70%), but other
        stressful events can also cause crises, such as trauma, surgery, a dental procedure, and
        major psychological distress.<a title="ref4" name="back-bib58"
                                        onmouseover="this.style.cursor='pointer'"
                                        onfocus="this.blur();"
                                        onclick="showPopupMulti('bib58');"><sup>58</sup></a><sup>, </sup><a
                title="ref4" name="back-bib59" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib59');"><sup>59</sup></a> Many
        crises result from clinicians not adjusting glucocorticoid dose appropriately, or at
        all—caused, to a large degree, by the poor knowledge and slow reaction time of physicians
        involved in the acute care of patients with adrenal insufficiency with incipient crisis.<a
                title="ref4" name="back-bib59" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib59');"><sup>59</sup></a><sup>, </sup><a title="ref4"
                                                                                    name="back-bib60"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib60');"><sup>60</sup></a>
        Patients with other comorbidities such as diabetes mellitus, diabetes insipidus, asthma, and
        premature ovarian failure are at higher risk, but these groups do not sufficiently
        discriminate patients with increased risk of adrenal crisis.<a title="ref4"
                                                                       name="back-bib58"
                                                                       onmouseover="this.style.cursor='pointer'"
                                                                       onfocus="this.blur();"
                                                                       onclick="showPopupMulti('bib58');"><sup>58</sup></a><sup>, </sup><a
                title="ref4" name="back-bib59" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib59');"><sup>59</sup></a> Symptoms
        include fatigue, nausea, vomiting, abdominal pain, muscle cramps, and hypotension, and
        effects can accelerate to hypovolaemic shock and coma. Hyponatraemia, hyperkalaemia, and
        prerenal failure are frequently noted; hypoglycaemia is rarely seen in adults, but is
        somewhat frequent in children, in whom it can substantially affect neurological outcome.</p>

    <p class="indent">Treatment includes prompt rehydration (1 L of physiological saline in the
        first hour, 500 mL in the second hour, followed by continuous fluid administration) and
        immediate parenteral administration of 100 mg hydrocortisone, followed by 200 mg per 24 h,
        ideally via continuous intravenous infusion, or alternatively in three to four doses per day
        via intravenous or intramuscular injection. Patients' vital signs and regular assessment of
        serum electrolytes should be monitored. If patients are clinically stable, then
        glucocorticoid dose can be quickly tapered to the usual maintenance dose over 24—72 h.
        Mineralocorticoid administration should be started as soon as total daily hydrocortisone
        dose is lower than 50 mg.<a title="References" name="back-bib25"
                                    onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                    onclick="showPopupMulti('bib25');"><sup>25</sup></a></p>

    <p class="indent">To avoid fatal outcomes, adequate prevention and treatment of adrenal crisis
        is of highest importance. Adrenal insufficiency is a rare disease, and therefore many
        physicians are not familiar with its management, often resulting in critical delays in
        emergency treatment. Education for patients and relatives must include information about
        correct adjustment of glucocorticoid replacement, symptom awareness, and use of steroid
        emergency cards and medical alert bracelets (<a title="" href="#box3" name="back-box3"
                                                        class="ja50-ce-cross-ref">panel 3</a>). The
        development and rollout of a steroid emergency card across Europe is continuing, aiming to
        encourage the treating physician to immediately give hydrocortisone in imminent crisis.</p>

    <div class="ja50-ce-textbox" id="box3">
        <div class="ja50-ce-textbox-label">Panel 3</div>
        <div class="ja50-ce-textbox-caption"><p class="normal">Action points and interventions for
            prevention of adrenal crisis</p></div>
        <div class="ja50-ce-textbox-body1">
            <div id="lv_0021" class="level1"></div>
            <p class="indent1"><strong>Identify and define the problem</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Steroid emergency card (check if available and updated)</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Medical alert bracelet or necklace: “Adrenal insufficiency—needs steroids!”</span></span></span>
            </p>

            <p class="indent"><strong>Educate patient (and partner or parents)</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Sick day rule one: double the routine oral glucocorticoid dose when the patient has a fever, needs bedrest due to illness, or needs antibiotics for an infection</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Sick day rule two: inject glucocorticoid drug intramuscularly or intravenously in severe illness, trauma, persistent vomiting, when fasting for a procedure (eg, colonoscopy), or during surgical intervention</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Special attention to: explaining the reason for dose adjustment in stress or sickness; discussing the situations needing dose adjustment; discussing symptoms and signs of emergency adrenal crisis; teaching parenteral self-administration of glucocorticoid preparation; and enforcing the need to go to hospital after emergency injection</span></span></span>
            </p>

            <p class="indent"><strong>Provide patient with:</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Sufficient supply of hydrocortisone and fludrocortisone (accounting for possible sick days)</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Hydrocortisone emergency injection kit prescription (vials of 100 mg hydrocortisone, syringes, and needles; alternatively, hydrocortisone or prednisolone suppositories)</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Leaflet with information on adrenal crisis and hospitalisation to be shown to health-care staff, advise clearly about the need to inject 100 mg hydrocortisone immediately intravenously or intramuscularly followed by continuous infusion of 200 mg over 24 h</span></span><span
                    class="list-item"><span class="ja50-ce-list-item-label">•</span> <span
                    class="list-item-content">Emergency phone number of endocrine specialist team</span></span></span>
            </p>

            <p class="indent"><strong>Follow-up</strong></p>

            <p class="indent"><span class="ja50-ce-list"><span class="list-item"><span
                    class="ja50-ce-list-item-label">•</span> <span class="list-item-content">Reinforce education and confirm understanding during each follow-up visit (at least every year in a patient without specific problems or recent crises, otherwise more frequently)</span></span></span>
            </p></div>
    </div>
    <p class="indent">Emergency self-administration of hydrocortisone is of key importance to
        prevent crisis-related morbidity and mortality. In a 2006 survey, 66% of patients with
        Addison's disease reporting a crisis had relied on medical personnel to give the first
        treatment; only 12% of patients self-administered a hydrocortisone injection, with another
        17% treated by a close person. Almost a third of patients did not have an emergency
        injection kit (<a title="" href="#box3" name="back-box3" class="ja50-ce-cross-ref">panel
            3</a>).<a title="References" name="back-bib58" onmouseover="this.style.cursor='pointer'"
                      onfocus="this.blur();" onclick="showPopupMulti('bib58');"><sup>58</sup></a> As
        an alternative to intramuscular injection, which some patients are hesitant to give
        promptly, subcutaneous injections can be used, generating similar pharmacokinetics to
        intramuscular injection.<a title="References" name="back-bib61"
                                   onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                   onclick="showPopupMulti('bib61');"><sup>61</sup></a>
        Suppositories containing 100 mg of prednisolone can be used, depending on the patient's
        preference.<a title="References" name="back-bib62" onmouseover="this.style.cursor='pointer'"
                      onfocus="this.blur();" onclick="showPopupMulti('bib62');"><sup>62</sup></a>
        Progress in this area will be achieved once pharmaceutical companies achieve the development
        of a suitable self-injection device similar to the epinephrine autoinjector for patients
        with anaphylaxis.</p>

    <div id="cesec170"></div>
    <div id="lv_0022" class="level2">Fertility and pregnancy</div>
    <p class="indent">Women with Addison's disease have reduced rates of fertility, even after
        exclusion of those with premature ovarian failure.<a title="ref4" name="back-bib63"
                                                             onmouseover="this.style.cursor='pointer'"
                                                             onfocus="this.blur();"
                                                             onclick="showPopupMulti('bib63');"><sup>63</sup></a><sup>, </sup><a
                title="ref4" name="back-bib64" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib64');"><sup>64</sup></a> Risk of
        miscarriage is increased. Women with Addison's disease also have higher rates of preterm
        birth and caesarean delivery and are more likely to have newborns with low birthweight (&lt;2500
        g).<a title="References" name="back-bib64" onmouseover="this.style.cursor='pointer'"
              onfocus="this.blur();" onclick="showPopupMulti('bib64');"><sup>64</sup></a> Women with
        adrenal insufficiency due to congenital adrenal hyperplasia might often need caesarean
        delivery. Women with adrenal insufficiency due to congenital adrenal hyperplasia might need
        caesarean delivery if they underwent a previous genital correction surgery. Other women with
        adrenal insufficiency should not need caesarian delivery any more frequently than do women
        without adrenal insufficiency.</p>

    <p class="indent">Total cortisol concentrations are two to three times higher in pregnancy,<a
            title="References" name="back-bib65" onmouseover="this.style.cursor='pointer'"
            onfocus="this.blur();" onclick="showPopupMulti('bib65');"><sup>65</sup></a> rising in
        the first trimester due to rises in corticosteroid-binding globulin concentrations and
        increased cortisol half-life due to decreases in hepatic clearance of the bound hormone.<a
                title="References" name="back-bib66" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib66');"><sup>66</sup></a> However,
        from the 22nd week of gestation onwards, free cortisol concentrations also increase
        substantially, most likely because of increased placental production of
        corticotropin-releasing hormone. This rise results in hypertrophy of adrenal glands and
        increased responsiveness to synacthen as pregnancy progresses,<a title="ref4"
                                                                         name="back-bib35"
                                                                         onmouseover="this.style.cursor='pointer'"
                                                                         onfocus="this.blur();"
                                                                         onclick="showPopupMulti('bib35');"><sup>35</sup></a><sup>, </sup><a
                title="ref4" name="back-bib67" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib67');"><sup>67</sup></a> with
        diagnostic and therapeutic implications for women.</p>

    <p class="indent">Adrenal insufficiency symptoms overlap with features that might be related to
        pregnancy itself, such as fatigue, hyponatraemia, nausea, and vomiting. The
        adrenocorticotropic hormone stimulation test remains the test of choice for pregnant women
        when adrenal insufficiency is suspected. In a study of a small group of healthy pregnant
        women (4 women in the first trimester, 16 in the second trimester, and 16 in the third), the
        peak total cortisol response after adrenocorticotropic hormone injection was significantly
        higher than it was after pregnancy (median of 1000 nmol/L [37 μg/dL] in the second and third
        trimester <i>vs</i> 700 nmol/L [26 μg/dL] post-partum).<a title="References"
                                                                  name="back-bib35"
                                                                  onmouseover="this.style.cursor='pointer'"
                                                                  onfocus="this.blur();"
                                                                  onclick="showPopupMulti('bib35');"><sup>35</sup></a>
        Thus, it is prudent to use higher total cortisol cutoffs to confirm a diagnosis of adrenal
        insufficiency until more data are available; recommended diagnostic cutoffs are 700 nmol/L
        (25 μg/dL) for the first trimester, 800 nmol/L (29 μg/dL) for the second trimester, and 900
        nmol/L (32 μg/dL) for the third trimester.<a title="References" name="back-bib68"
                                                     onmouseover="this.style.cursor='pointer'"
                                                     onfocus="this.blur();"
                                                     onclick="showPopupMulti('bib68');"><sup>68</sup></a>
        Although clinicians have reported adrenal crisis during pregnancy because glucocorticoid
        dose was not adapted,<a title="References" name="back-bib59"
                                onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                onclick="showPopupMulti('bib59');"><sup>59</sup></a> little evidence
        has been shown for an optimum amount of glucocorticoid replacement during pregnancy.<a
                title="References" name="back-bib69" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib69');"><sup>69</sup></a> Our
        usual practice is to increase hydrocortisone dose by about 20—40% during the third trimester
        to be consistent with the physiological increase in free cortisol.</p>

    <p class="indent">Clinical assessment of mineralocorticoid requirements during pregnancy is
        difficult, again because of overlapping unspecific symptoms such as oedema or postural
        hypotension. Sodium and potassium can be monitored in blood and urine; however, plasma renin
        is not informative as concentrations increase during pregnancy. Increases in progesterone
        concentrations during pregnancy have an antimineralocorticoid effect, thus adjustment of
        fludrocortisone dose is sometimes needed.<a title="References" name="back-bib70"
                                                    onmouseover="this.style.cursor='pointer'"
                                                    onfocus="this.blur();"
                                                    onclick="showPopupMulti('bib70');"><sup>70</sup></a>
    </p>

    <p class="indent">During delivery, hydrocortisone replacement should be similar to that given
        during major surgery—100 mg hydrocortisone intravenously at the onset of active labour
        (cervix dilation 4 cm or contractions every 5 min for 1 h, or both), followed by
        hydrocortisone 200 mg every 24 h via continuous intravenous infusion (or 50 mg
        hydrocortisone intravenous or intramuscular every 6 h) until after delivery. After delivery,
        hydrocortisone can be quickly tapered back to prepregnancy doses within 2—4 days.<a
                title="References" name="back-bib57" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib57');"><sup>57</sup></a></p>

    <div id="cesec180"></div>
    <div id="lv_0023" class="level2">Subjective health status</div>
    <p class="indent">Patients with primary and secondary adrenal insufficiency (even those with
        isolated adrenal insufficiency without any comorbidity) report reduced quality of life
        compared with healthy controls. This finding corresponds with a higher rate of working
        disability compared with the general population.<a title="ref4" name="back-bib3"
                                                           onmouseover="this.style.cursor='pointer'"
                                                           onfocus="this.blur();"
                                                           onclick="showPopupMulti('bib3');"><sup>3</sup></a><sup>, </sup><a
                title="ref4" name="back-bib4" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib4');"><sup>4</sup></a><sup>, </sup><a title="ref4"
                                                                                  name="back-bib71"
                                                                                  onmouseover="this.style.cursor='pointer'"
                                                                                  onfocus="this.blur();"
                                                                                  onclick="showPopupMulti('bib71');"><sup>71</sup></a>
        Quality of life is negatively correlated with age of onset of adrenal insufficiency (ie, the
        younger the onset, the worse an individual's quality of life). Female sex, comorbidities,
        and a delayed diagnosis of adrenal insufficiency are risk factors for decreased quality of
        life.<a title="References" name="back-bib17" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib17');"><sup>17</sup></a> Reports
        of low quality of life despite established replacement therapy might be related to
        glucocorticoid over-replacement or under-replacement, non-physiological circadian cortisol
        pattern generated by the currently available hydrocortisone preparations,<a title="ref4"
                                                                                    name="back-bib72"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib72');"><sup>72</sup></a><sup>, </sup><a
                title="ref4" name="back-bib73" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib73');"><sup>73</sup></a> or
        absence of adrenal androgen replacement.<a title="ref4" name="back-bib48"
                                                   onmouseover="this.style.cursor='pointer'"
                                                   onfocus="this.blur();"
                                                   onclick="showPopupMulti('bib48');"><sup>48</sup></a><sup>, </sup><a
                title="ref4" name="back-bib51" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib51');"><sup>51</sup></a> Hence,
        there is an urgent need for improved replacement strategies.<a title="References"
                                                                       name="back-bib73"
                                                                       onmouseover="this.style.cursor='pointer'"
                                                                       onfocus="this.blur();"
                                                                       onclick="showPopupMulti('bib73');"><sup>73</sup></a>
        In retrospective analyses, quality of life was negatively correlated with glucocorticoid
        dose and was still reduced in individuals receiving DHEA replacement.<a title="References"
                                                                                name="back-bib74"
                                                                                onmouseover="this.style.cursor='pointer'"
                                                                                onfocus="this.blur();"
                                                                                onclick="showPopupMulti('bib74');"><sup>74</sup></a>
        This suggests that non-physiological glucocorticoid replacement could have a major effect. A
        small study showed an increase in quality of life after restoration of the circadian profile
        by hydrocortisone via insulin pump.<a title="References" name="back-bib75"
                                              onmouseover="this.style.cursor='pointer'"
                                              onfocus="this.blur();"
                                              onclick="showPopupMulti('bib75');"><sup>75</sup></a>
        However, convincing data are still needed for the optimum interventions to improve quality
        of life in these patients.</p>

    <div id="cesec190"></div>
    <div id="lv_0024" class="level2">Prognosis</div>
    <p class="indent">Generally, the prognosis is good for appropriately diagnosed and treated
        patients with adrenal insufficiency. However, adrenal insufficiency remains a potentially
        lethal disorder and adrenal crisis remains one of the frequent causes of death, particularly
        in patients younger than 40 years.<a title="References" name="back-bib76"
                                             onmouseover="this.style.cursor='pointer'"
                                             onfocus="this.blur();"
                                             onclick="showPopupMulti('bib76');"><sup>76</sup></a>
        Standardised mortality rates for patients with primary and secondary adrenal insufficiency
        are more than double of those for an age-adjusted and sex-adjusted control population.<a
                title="ref4" name="back-bib5" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib5');"><sup>5</sup></a><sup>, </sup><a title="ref4"
                                                                                  name="back-bib77"
                                                                                  onmouseover="this.style.cursor='pointer'"
                                                                                  onfocus="this.blur();"
                                                                                  onclick="showPopupMulti('bib77');"><sup>77</sup></a><sup>, </sup><a
                title="ref4" name="back-bib78" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();"
                onclick="showPopupMulti('bib78');"><sup>78</sup></a><sup>, </sup><a title="ref4"
                                                                                    name="back-bib79"
                                                                                    onmouseover="this.style.cursor='pointer'"
                                                                                    onfocus="this.blur();"
                                                                                    onclick="showPopupMulti('bib79');"><sup>79</sup></a>
        Increased mortality in primary adrenal insufficiency is linked to increased rate of
        respiratory infections<a title="References" name="back-bib78"
                                 onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                                 onclick="showPopupMulti('bib78');"><sup>78</sup></a> and,
        particularly for patients younger than 40 years, to adrenal crisis and sudden death.<a
                title="References" name="back-bib76" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib76');"><sup>76</sup></a></p>

    <p class="indent">In clinical practice, a large proportion of patients regularly take
        replacement doses that are in excess of normal physiological concentrations, often to try to
        alleviate symptoms. Previous overestimates of physiological cortisol production rates might
        have led to prescribed doses in excess of physiological requirements.<a title="References"
                                                                                name="back-bib80"
                                                                                onmouseover="this.style.cursor='pointer'"
                                                                                onfocus="this.blur();"
                                                                                onclick="showPopupMulti('bib80');"><sup>80</sup></a>
        Furthermore, patients often take extra doses of hydrocortisone. For example, 52% of patients
        with adrenal insufficiency reported taking extra doses one to three times a month and 20%
        took extra doses more often.<a title="References" name="back-bib4"
                                       onmouseover="this.style.cursor='pointer'"
                                       onfocus="this.blur();"
                                       onclick="showPopupMulti('bib4');"><sup>4</sup></a>
        Supraphysiological glucocorticoid replacement is associated with increased mortality,<a
                title="References" name="back-bib81" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib81');"><sup>81</sup></a>
        cardiovascular risk, and bone fragility. There is a clear hydrocortisone dose response with
        BMI, triglyceride concentrations, and total and LDL cholesterol concentrations in
        hypopituitary patients. However, all patients taking 20 mg or less of hydrocortisone per day
        had metabolic profiles similar to those with intact hypothalamic-pituitary-adrenal axis.<a
                title="References" name="back-bib82" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib82');"><sup>82</sup></a> A higher
        prevalence of central adiposity, impaired glucose tolerance, and dyslipidaemia has been
        noted in patients with Addison's disease taking 30 mg hydrocortisone.<a title="References"
                                                                                name="back-bib83"
                                                                                onmouseover="this.style.cursor='pointer'"
                                                                                onfocus="this.blur();"
                                                                                onclick="showPopupMulti('bib83');"><sup>83</sup></a>
        Interestingly, a more adverse metabolic response was noted when hydrocortisone was given in
        the evening.<a title="References" name="back-bib84"
                       onmouseover="this.style.cursor='pointer'" onfocus="this.blur();"
                       onclick="showPopupMulti('bib84');"><sup>84</sup></a> Studies have also shown
        an increased incidence of osteoporosis in patients receiving more than 30 mg of
        hydrocortisone or 7·5 mg prednisone per day<a title="ref4" name="back-bib69"
                                                      onmouseover="this.style.cursor='pointer'"
                                                      onfocus="this.blur();"
                                                      onclick="showPopupMulti('bib69');"><sup>69</sup></a><sup>, </sup><a
                title="ref4" name="back-bib43" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib43');"><sup>43</sup></a> and an
        increased risk of fractures in patients with Addison's disease taking these doses.<a
                title="References" name="back-bib85" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib85');"><sup>85</sup></a> However,
        the recommended replacement dose of 15—25 mg per day does not affect bone density.<a
                title="References" name="back-bib86" onmouseover="this.style.cursor='pointer'"
                onfocus="this.blur();" onclick="showPopupMulti('bib86');"><sup>86</sup></a></p>

    <div id="cesec200"></div>
    <div id="lv_0025" class="level2">Conclusion</div>
    <p class="indent">Despite large advances, the diagnosis and management of adrenal insufficiency
        remains a challenge and needs consideration of special situations to tailor replacement
        therapy to the individual patient. Raising awareness and education in medical teams and
        patients about adrenal insufficiency and management of adrenal crisis is of importance to
        improve clinical outcomes. Whether modified-release hydrocortisone drugs will provide a
        novel avenue for more physiologically based replacement to improve quality of life and
        prevent metabolic outcomes remains to be shown.</p>

    <div id="cesec210"></div>
    <div id="lv_0026" class="level2">Search strategy and selection criteria</div>
    <p class="indent">

    <div class="ja50-ce-textbox" id="cetextbox10">
        <div class="ja50-ce-textbox-body1">
            <div id="lv_0027" class="level1"></div>
            <p class="indent1">We searched Ovid Medline In-Process and Other Non-Indexed Citations,
                Ovid Medline, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, and
                Ovid Cochrane Database of Systematic Reviews. Search terms included “adrenal
                insufficiency”, “hypoadrenalism”, “adrenal hypofunction”, “Addison's disease”,
                “adrenoleukodystrophy”, and “hypoaldosteronism”. We excluded case reports, letters,
                and commentaries. We selected all relevant articles published in English from Jan 1,
                2003, to March 18, 2014, to include developments since publication of our previous
                Review in <i>The Lancet</i>.<a title="References" name="back-bib9"
                                               onmouseover="this.style.cursor='pointer'"
                                               onfocus="this.blur();"
                                               onclick="showPopupMulti('bib9');"><sup>9</sup></a>
            </p></div>
    </div>
    </p><p class="indent"><strong>Contributors</strong></p>

    <p class="indent">All authors participated in the literature search, writing and editing, and
        the design of the table, panels, and figures.</p>

    <p class="indent"><strong>Declaration of interests</strong></p>

    <p class="indent">WA acts as a consultant to Diurnal, outside the submitted work. SH serves as a
        consultant for ViroPharma, outside the submitted work. JT and IB declare no competing
        interests.</p>

    <div class="ja50-ce-appendicies" id="ja50-ce-appendicies">
        <div id="sec1"></div>
        <div id="lv_0028" class="level4">Supplementary Material</div>
        <p class="indent">

        <div style="border: 1px solid #000000; padding: 5px; margin: 10px 0px " id="ecomp10"><p
                class="caption"><b>Supplementary appendix</b>
             
        </p></div>
        </p></div>
</div>
<div id="yoasNoAbstractFragment"></div>
<hr class="hrreference"></hr>
<div id="bibliography" class="bibliography">
    <div id="lv_0029" class="level2">References</div>
    <div class="refshow" id="bib1"><a class="back-bib" href="#back-bib1">1</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kong</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Jeffcoate</span> <span
            class="ja50-ce-given-name">W</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Eighty-six cases of Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">1994</span>; <span
                class="ja50-sb-volume-nr">41</span>: </span><span
                class="ja50-sb-pages">757-761</span>. </span></div>
    <div class="refshow" id="bib2"><a class="back-bib" href="#back-bib2">2</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Laureti</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Vecchi</span> <span class="ja50-ce-given-name">L</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Santeusanio</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Falorni</span> <span class="ja50-ce-given-name">A</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Is the prevalence of Addison's disease underestimated?</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Med</span></span> <span
                class="ja50-sb-date">1999</span>; <span class="ja50-sb-volume-nr">84</span>: </span><span
                class="ja50-sb-pages">1762</span>. </span></div>
    <div class="refshow" id="bib3"><a class="back-bib" href="#back-bib3">3</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Husebye</span> <span class="ja50-ce-given-name">E</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">High prevalence and increasing incidence of Addison's disease in western Norway</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">2002</span>; <span
                class="ja50-sb-volume-nr">56</span>: </span><span
                class="ja50-sb-pages">781-791</span>. </span></div>
    <div class="refshow" id="bib4"><a class="back-bib" href="#back-bib4">4</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Erichsen</span> <span
            class="ja50-ce-given-name">MM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Skinningsrud</span> <span
            class="ja50-ce-given-name">B</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2009</span>; <span class="ja50-sb-volume-nr">94</span>: </span><span
                class="ja50-sb-pages">4882-4890</span>. </span></div>
    <div class="refshow" id="bib5"><a class="back-bib" href="#back-bib5">5</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Tomlinson</span> <span
            class="ja50-ce-given-name">JW</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Holden</span> <span class="ja50-ce-given-name">N</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Hills</span> <span
            class="ja50-ce-given-name">R</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Association between premature mortality and hypopituitairism</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Lancet</span></span> <span
                class="ja50-sb-date">2001</span>; <span
                class="ja50-sb-volume-nr">357</span>: </span><span
                class="ja50-sb-pages">425-431</span>. </span></div>
    <div class="refshow" id="bib6"><a class="back-bib" href="#back-bib6">6</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Addison</span> <span class="ja50-ce-given-name">T</span></span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-title"><span class="ja50-sb-maintitle">On the constitutional and local effects of disease of the suprarenal capsules</span></span>. <span
                class="ja50-sb-publisher">London: Warren and Son, </span><span class="ja50-sb-date">1855</span>. </span>
    </div>
    <div class="refshow" id="bib7"><a class="back-bib" href="#back-bib7">7</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Simpson</span> <span class="ja50-ce-given-name">SL</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The use of synthetic desoxycorticosterone acetate in Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Lancet</span></span> <span
                class="ja50-sb-date">1938</span>; <span
                class="ja50-sb-volume-nr">232</span>: </span><span
                class="ja50-sb-pages">557-558</span>. </span></div>
    <div class="refshow" id="bib8"><a class="back-bib" href="#back-bib8">8</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Benedek</span> <span class="ja50-ce-given-name">TG</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">History of the development of corticosteroid therapy</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Exp Rheumatol</span></span> <span
                class="ja50-sb-date">2011</span>; <span class="ja50-sb-volume-nr">29</span> (<span
                class="ja50-sb-issue-nr">suppl 68</span>): </span><span
                class="ja50-sb-pages">S5-12</span>. </span></div>
    <div class="refshow" id="bib9"><a class="back-bib" href="#back-bib9">9</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Allolio</span> <span class="ja50-ce-given-name">B</span></span></span>. <span
            class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Adrenal insufficiency</span></span></span>. <span
            class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Lancet</span></span> <span
            class="ja50-sb-date">2003</span>; <span
            class="ja50-sb-volume-nr">361</span>: </span><span
            class="ja50-sb-pages">1881-1893</span>. </span></div>
    <div class="refshow" id="bib10"><a class="back-bib" href="#back-bib10">10</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Betterle</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Dal Pra</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mantero</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Zanchetta</span> <span
            class="ja50-ce-given-name">R</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Endocr Rev</span></span> <span
                class="ja50-sb-date">2002</span>; <span class="ja50-sb-volume-nr">23</span>: </span><span
                class="ja50-sb-pages">327-364</span>. </span></div>
    <div class="refshow" id="bib11"><a class="back-bib" href="#back-bib11">11</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mitchell</span> <span
            class="ja50-ce-given-name">AL</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Pearce</span> <span class="ja50-ce-given-name">SHS</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Autoimmune Addison disease: pathophysiology and genetic complexity</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Nat Rev Endocrinol</span></span> <span
                class="ja50-sb-date">2012</span>; <span
                class="ja50-sb-volume-nr">8</span>: </span><span
                class="ja50-sb-pages">306-316</span>. </span></div>
    <div class="refshow" id="bib12"><a class="back-bib" href="#back-bib12">12</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Myhre</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Undlien</span> <span
            class="ja50-ce-given-name">D</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span class="ja50-ce-given-name">K</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Autoimmune adrenocortical failure in Norway autoantibodies and human antigen class II associations related to clinical features</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2002</span>; <span class="ja50-sb-volume-nr">87</span>: </span><span
                class="ja50-sb-pages">618-623</span>. </span></div>
    <div class="refshow" id="bib13"><a class="back-bib" href="#back-bib13">13</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Regal</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Paramo</span> <span class="ja50-ce-given-name">C</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Sierra</span> <span
            class="ja50-ce-given-name">SM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Garcia-Mayor</span> <span
            class="ja50-ce-given-name">RV</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2001</span>; <span class="ja50-sb-volume-nr">55</span>: </span><span
                class="ja50-sb-pages">735-740</span>. </span></div>
    <div class="refshow" id="bib14"><a class="back-bib" href="#back-bib14">14</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Schlaghecke</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kornely</span> <span
            class="ja50-ce-given-name">E</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Santen</span> <span
            class="ja50-ce-given-name">RT</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ridderskamp</span> <span
            class="ja50-ce-given-name">P</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">N Engl J Med</span></span> <span
                class="ja50-sb-date">1992</span>; <span
                class="ja50-sb-volume-nr">326</span>: </span><span
                class="ja50-sb-pages">226-230</span>. </span></div>
    <div class="refshow" id="bib15"><a class="back-bib" href="#back-bib15">15</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Henzen</span> <span class="ja50-ce-given-name">C</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Suter</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lerch</span> <span
            class="ja50-ce-given-name">E</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Urbinelli</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Schorno</span> <span
            class="ja50-ce-given-name">XH</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Briner</span> <span class="ja50-ce-given-name">VA</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Lancet</span></span> <span
                class="ja50-sb-date">2000</span>; <span
                class="ja50-sb-volume-nr">355</span>: </span><span
                class="ja50-sb-pages">542-545</span>. </span></div>
    <div class="refshow" id="bib16"><a class="back-bib" href="#back-bib16">16</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Chortis</span> <span
            class="ja50-ce-given-name">V</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Taylor</span> <span
            class="ja50-ce-given-name">AE</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Schneider</span> <span
            class="ja50-ce-given-name">P</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2013</span>; <span class="ja50-sb-volume-nr">98</span>: </span><span
                class="ja50-sb-pages">161-171</span>. </span></div>
    <div class="refshow" id="bib17"><a class="back-bib" href="#back-bib17">17</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bleicken</span> <span
            class="ja50-ce-given-name">B</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hahner</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Ventz</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Quinkler</span> <span class="ja50-ce-given-name">M</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Am J Med Sci</span></span> <span
                class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">339</span>: </span><span
                class="ja50-sb-pages">525-531</span>. </span></div>
    <div class="refshow" id="bib18"><a class="back-bib" href="#back-bib18">18</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mayenknecht</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Diederich</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bahr</span> <span
            class="ja50-ce-given-name">V</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Plockinger</span> <span
            class="ja50-ce-given-name">U</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Oelkers</span> <span class="ja50-ce-given-name">W</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">1998</span>; <span class="ja50-sb-volume-nr">83</span>: </span><span
                class="ja50-sb-pages">1558-1562</span>. </span></div>
    <div class="refshow" id="bib19"><a class="back-bib" href="#back-bib19">19</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Debono</span> <span class="ja50-ce-given-name">M</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Ghobadi</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Rostami-Hodjegan</span> <span
            class="ja50-ce-given-name">A</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Modified-release hydrocortisone to provide circadian cortisol profiles</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2009</span>; <span class="ja50-sb-volume-nr">94</span>: </span><span
                class="ja50-sb-pages">1548-1554</span>. </span></div>
    <div class="refshow" id="bib20"><a class="back-bib" href="#back-bib20">20</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ross</span> <span
            class="ja50-ce-given-name">I</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Boulle</span> <span class="ja50-ce-given-name">A</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Soule</span> <span
            class="ja50-ce-given-name">S</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Autoimmunity predominates in a large South African cohort with Addison's disease of mainly European descent despite long-standing disease and is associated with HLA DQB*0201</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">73</span>: </span><span
                class="ja50-sb-pages">291-298</span>. </span></div>
    <div class="refshow" id="bib21"><a class="back-bib" href="#back-bib21">21</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Eisenbarth</span> <span
            class="ja50-ce-given-name">GS</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Wilson</span> <span
            class="ja50-ce-given-name">PW</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ward</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Buckley</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lebovita</span> <span class="ja50-ce-given-name">H</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The polyglandular failure syndrome: disease inheritance, HLA type, and immune function</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Ann Intern Med</span></span> <span class="ja50-sb-date">1979</span>; <span
                class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">528-533</span>. </span></div>
    <div class="refshow" id="bib22"><a class="back-bib" href="#back-bib22">22</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Diederich</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Franzen</span> <span
            class="ja50-ce-given-name">NF</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bahr</span> <span
            class="ja50-ce-given-name">V</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Oelkers</span> <span class="ja50-ce-given-name">W</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2003</span>; <span
                class="ja50-sb-volume-nr">148</span>: </span><span
                class="ja50-sb-pages">609-617</span>. </span></div>
    <div class="refshow" id="bib23"><a class="back-bib" href="#back-bib23">23</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Maghnie</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Uga</span> <span
            class="ja50-ce-given-name">E</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Temporini</span> <span
            class="ja50-ce-given-name">F</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2005</span>; <span
                class="ja50-sb-volume-nr">152</span>: </span><span
                class="ja50-sb-pages">735-741</span>. </span></div>
    <div class="refshow" id="bib24"><a class="back-bib" href="#back-bib24">24</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Dorin</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Qualls</span> <span class="ja50-ce-given-name">C</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Crapo</span> <span
            class="ja50-ce-given-name">L</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Diagnosis of adrenal insufficiency</span></span></span>. <span
            class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Ann Intern Med</span></span> <span
            class="ja50-sb-date">2003</span>; <span
            class="ja50-sb-volume-nr">139</span>: </span><span class="ja50-sb-pages">194-204</span>. </span>
    </div>
    <div class="refshow" id="bib25"><a class="back-bib" href="#back-bib25">25</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Oelkers</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Diederich</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bahr</span> <span
            class="ja50-ce-given-name">V</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Diagnosis and therapy surveillance in Addison's disease: rapid adenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">1992</span>; <span class="ja50-sb-volume-nr">75</span>: </span><span
                class="ja50-sb-pages">259-264</span>. </span></div>
    <div class="refshow" id="bib26"><a class="back-bib" href="#back-bib26">26</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Watts</span> <span class="ja50-ce-given-name">NB</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Tindall</span> <span
            class="ja50-ce-given-name">GT</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Rapid assessment of corticotropin reserve after pituitary surgery</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">JAMA</span></span> <span class="ja50-sb-date">1988</span>; <span
                class="ja50-sb-volume-nr">259</span>: </span><span
                class="ja50-sb-pages">708-711</span>. </span></div>
    <div class="refshow" id="bib27"><a class="back-bib" href="#back-bib27">27</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Auchus</span> <span
            class="ja50-ce-given-name">RJ</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Shewbridge</span> <span
            class="ja50-ce-given-name">RK</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Shepherd</span> <span
            class="ja50-ce-given-name">MD</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Which patients benefit from provocative adrenal testing after transsphenoidal pituitary surgery?</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">1997</span>; <span class="ja50-sb-volume-nr">46</span>: </span><span
                class="ja50-sb-pages">21-27</span>. </span></div>
    <div class="refshow" id="bib28"><a class="back-bib" href="#back-bib28">28</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Agha</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Tomlinson</span> <span
            class="ja50-ce-given-name">JW</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Clark</span> <span class="ja50-ce-given-name">PM</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Holder</span> <span
            class="ja50-ce-given-name">G</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Stewart</span> <span class="ja50-ce-given-name">PM</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The long—term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">43-47</span>. </span></div>
    <div class="refshow" id="bib29"><a class="back-bib" href="#back-bib29">29</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lee</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Greenfield</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ho</span> <span
            class="ja50-ce-given-name">K</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Factors determining inadequate hypoglycemia during insulin tolerance testing (ITT) after pituitary surgery</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2009</span>; <span class="ja50-sb-volume-nr">71</span>: </span><span
                class="ja50-sb-pages">82-85</span>. </span></div>
    <div class="refshow" id="bib30"><a class="back-bib" href="#back-bib30">30</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Berg</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Meinel</span> <span class="ja50-ce-given-name">T</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Lahner</span> <span
            class="ja50-ce-given-name">H</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mann</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Petersenn</span> <span
            class="ja50-ce-given-name">S</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">162</span>: </span><span
                class="ja50-sb-pages">853-859</span>. </span></div>
    <div class="refshow" id="bib31"><a class="back-bib" href="#back-bib31">31</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Winqvist</span> <span
            class="ja50-ce-given-name">O</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Karlsson</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kampe</span> <span
            class="ja50-ce-given-name">O</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">21-Hydroxylase, a major autoantigen in idiopathic Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Lancet</span></span> <span
                class="ja50-sb-date">1992</span>; <span
                class="ja50-sb-volume-nr">339</span>: </span><span
                class="ja50-sb-pages">1552-1562</span>. </span></div>
    <div class="refshow" id="bib32"><a class="back-bib" href="#back-bib32">32</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Abrams</span> <span
            class="ja50-ce-given-name">HL</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Spiro</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Goldstein</span> <span
            class="ja50-ce-given-name">N</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Metastases in carcinoma; analysis of 1000 autopsied cases</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Cancer</span></span> <span
                class="ja50-sb-date">1950</span>; <span
                class="ja50-sb-volume-nr">3</span>: </span><span class="ja50-sb-pages">74-85</span>. </span>
    </div>
    <div class="refshow" id="bib33"><a class="back-bib" href="#back-bib33">33</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Brien</span> <span
            class="ja50-ce-given-name">T</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Clerico</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Del Chicca</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Zucchelli</span> <span
            class="ja50-ce-given-name">G</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">The apparent free cortisol concentration and the free cortisol index: a comparative study</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Nucl Med Allied Sci</span></span> <span
                class="ja50-sb-date">1981</span>; <span class="ja50-sb-volume-nr">25</span>: </span><span
                class="ja50-sb-pages">49-51</span>. </span></div>
    <div class="refshow" id="bib34"><a class="back-bib" href="#back-bib34">34</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Marcus-Perlman</span> <span class="ja50-ce-given-name">Y</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Tordjman</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Greenman</span> <span class="ja50-ce-given-name">Y</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Low-dose ACTH (1microg) salivary test: a potential alternative to the classical blood test</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">2006</span>; <span
                class="ja50-sb-volume-nr">64</span>: </span><span
                class="ja50-sb-pages">215-218</span>. </span></div>
    <div class="refshow" id="bib35"><a class="back-bib" href="#back-bib35">35</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Suri</span> <span
            class="ja50-ce-given-name">D</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Moran</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hibbard</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kasza</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Weiss</span> <span
            class="ja50-ce-given-name">R</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">3866-3872</span>. </span></div>
    <div class="refshow" id="bib36"><a class="back-bib" href="#back-bib36">36</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Stokes</span> <span class="ja50-ce-given-name">F</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Bailey</span> <span
            class="ja50-ce-given-name">L</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ganguli</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Davison</span> <span class="ja50-ce-given-name">A</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Assessment of endogenous, oral and inhaled steroid cross-reactivity in the Roche cortisol immunoassay</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Ann Clin Biochem</span></span> <span class="ja50-sb-date">2013</span>; <span
                class="ja50-sb-volume-nr">51</span>: </span><span
                class="ja50-sb-pages">503-506</span>. </span></div>
    <div class="refshow" id="bib37"><a class="back-bib" href="#back-bib37">37</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Dinsen</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Baslund</span> <span
            class="ja50-ce-given-name">B</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Klose</span> <span class="ja50-ce-given-name">M</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Intern Med</span></span> <span class="ja50-sb-date">2013</span>; <span
                class="ja50-sb-volume-nr">24</span>: </span><span
                class="ja50-sb-pages">714-720</span>. </span></div>
    <div class="refshow" id="bib38"><a class="back-bib" href="#back-bib38">38</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Holme</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Tomlinson</span> <span
            class="ja50-ce-given-name">JW</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Stockley</span> <span
            class="ja50-ce-given-name">RA</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Stewart</span> <span
            class="ja50-ce-given-name">PM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Barlow</span> <span class="ja50-ce-given-name">N</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Sullivan</span> <span
            class="ja50-ce-given-name">AL</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur Respir J</span></span> <span
                class="ja50-sb-date">2008</span>; <span class="ja50-sb-volume-nr">32</span>: </span><span
                class="ja50-sb-pages">1047-1052</span>. </span></div>
    <div class="refshow" id="bib39"><a class="back-bib" href="#back-bib39">39</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Paton</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Jardine</span> <span
            class="ja50-ce-given-name">E</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">McNeill</span> <span class="ja50-ce-given-name">E</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Arch Dis Child</span></span> <span class="ja50-sb-date">2006</span>; <span
                class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">808-813</span>. </span></div>
    <div class="refshow" id="bib40"><a class="back-bib" href="#back-bib40">40</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Priftis</span> <span
            class="ja50-ce-given-name">KN</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Papadimitriou</span> <span class="ja50-ce-given-name">A</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Anthracopoulos</span> <span
            class="ja50-ce-given-name">MB</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Adrenal function improves in asthmatic children on inhaled steroids: a longitudinal study</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Neuroimmunomodulation</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">13</span>: </span><span
                class="ja50-sb-pages">56-62</span>. </span></div>
    <div class="refshow" id="bib41"><a class="back-bib" href="#back-bib41">41</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Esteban</span> <span
            class="ja50-ce-given-name">N</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Loughlin</span> <span
            class="ja50-ce-given-name">T</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Yergey</span> <span class="ja50-ce-given-name">A</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">JCEM</span></span> <span class="ja50-sb-date">1991</span>; <span
                class="ja50-sb-volume-nr">72</span>: </span><span class="ja50-sb-pages">39-45</span>. </span>
    </div>
    <div class="refshow" id="bib42"><a class="back-bib" href="#back-bib42">42</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mah</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Jenkins</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Rostami-Hodjegan</span> <span
            class="ja50-ce-given-name">A</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">2004</span>; <span
                class="ja50-sb-volume-nr">61</span>: </span><span
                class="ja50-sb-pages">367-375</span>. </span></div>
    <div class="refshow" id="bib43"><a class="back-bib" href="#back-bib43">43</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Rosenthal</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hahner</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Allolio</span> <span
            class="ja50-ce-given-name">B</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol</span></span> <span class="ja50-sb-date">2006</span>; <span
                class="ja50-sb-volume-nr">64</span>: </span><span
                class="ja50-sb-pages">384-389</span>. </span></div>
    <div class="refshow" id="bib44"><a class="back-bib" href="#back-bib44">44</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Forss</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Batcheller</span> <span
            class="ja50-ce-given-name">G</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Skrtic</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Johannsson</span> <span
            class="ja50-ce-given-name">G</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency — a worldwide patient survey</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">BMC Endocr Disord</span></span> <span
                class="ja50-sb-date">2012</span>; <span class="ja50-sb-volume-nr">12</span>: </span><span
                class="ja50-sb-pages">8</span>. </span></div>
    <div class="refshow" id="bib45"><a class="back-bib" href="#back-bib45">45</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Merza</span> <span
            class="ja50-ce-given-name">Z</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Rostami-Hodjegan</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Memmott</span> <span class="ja50-ce-given-name">A</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">65</span>: </span><span
                class="ja50-sb-pages">45-50</span>. </span></div>
    <div class="refshow" id="bib46"><a class="back-bib" href="#back-bib46">46</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Whitaker</span> <span
            class="ja50-ce-given-name">MJ</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Debono</span> <span class="ja50-ce-given-name">M</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Huatan</span> <span
            class="ja50-ce-given-name">H</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Merke</span> <span class="ja50-ce-given-name">DP</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ross</span> <span
            class="ja50-ce-given-name">RJ</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2014</span>; <span class="ja50-sb-volume-nr">80</span>: </span><span
                class="ja50-sb-pages">554-561</span>. </span></div>
    <div class="refshow" id="bib47"><a class="back-bib" href="#back-bib47">47</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Klement</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hubold</span> <span class="ja50-ce-given-name">C</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Cords</span> <span
            class="ja50-ce-given-name">H</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">High-calorie glucose-rich food attenuates neuroglycopenic symptoms in patients with Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2010</span>; <span class="ja50-sb-volume-nr">95</span>: </span><span
                class="ja50-sb-pages">522-528</span>. </span></div>
    <div class="refshow" id="bib48"><a class="back-bib" href="#back-bib48">48</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Husebye</span> <span
            class="ja50-ce-given-name">ES</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Allolio</span> <span
            class="ja50-ce-given-name">B</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span class="ja50-ce-given-name">W</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Intern Med</span></span> <span
                class="ja50-sb-date">2014</span>; <span
                class="ja50-sb-volume-nr">275</span>: </span><span
                class="ja50-sb-pages">104-115</span>. </span></div>
    <div class="refshow" id="bib49"><a class="back-bib" href="#back-bib49">49</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Orentreich</span> <span
            class="ja50-ce-given-name">N</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Brind</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Rizer</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Vogelman</span> <span class="ja50-ce-given-name">J</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">1984</span>; <span class="ja50-sb-volume-nr">59</span>: </span><span
                class="ja50-sb-pages">551-555</span>. </span></div>
    <div class="refshow" id="bib50"><a class="back-bib" href="#back-bib50">50</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Callies</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Allolio</span> <span class="ja50-ce-given-name">B</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">DHEA replacement in women with adrenal insufficiency——pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Endocr Res</span></span> <span
                class="ja50-sb-date">2000</span>; <span class="ja50-sb-volume-nr">26</span>: </span><span
                class="ja50-sb-pages">505-511</span>. </span></div>
    <div class="refshow" id="bib51"><a class="back-bib" href="#back-bib51">51</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bilger</span> <span class="ja50-ce-given-name">M</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Speraw</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">LaFranchi</span> <span
            class="ja50-ce-given-name">SH</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hanna</span> <span
            class="ja50-ce-given-name">CE</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Androgen replacement in adolescents and young women with hypopituitarism</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Pediatr Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2005</span>; <span class="ja50-sb-volume-nr">18</span>: </span><span
                class="ja50-sb-pages">355-362</span>. </span></div>
    <div class="refshow" id="bib52"><a class="back-bib" href="#back-bib52">52</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Brooke</span> <span
            class="ja50-ce-given-name">AM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kalingag</span> <span
            class="ja50-ce-given-name">LA</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Miraki—Moud</span> <span
            class="ja50-ce-given-name">F</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">65</span>: </span><span
                class="ja50-sb-pages">673-680</span>. </span></div>
    <div class="refshow" id="bib53"><a class="back-bib" href="#back-bib53">53</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Binder</span> <span class="ja50-ce-given-name">G</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Weber</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ehrismann</span> <span
            class="ja50-ce-given-name">M</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2009</span>; <span class="ja50-sb-volume-nr">94</span>: </span><span
                class="ja50-sb-pages">1182-1190</span>. </span></div>
    <div class="refshow" id="bib54"><a class="back-bib" href="#back-bib54">54</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hunt</span> <span
            class="ja50-ce-given-name">PJ</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Gurnell</span> <span
            class="ja50-ce-given-name">EM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Huppert</span> <span class="ja50-ce-given-name">FA</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2000</span>; <span class="ja50-sb-volume-nr">85</span>: </span><span
                class="ja50-sb-pages">4650-4656</span>. </span></div>
    <div class="refshow" id="bib55"><a class="back-bib" href="#back-bib55">55</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Pearce</span> <span
            class="ja50-ce-given-name">SH</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mitchell</span> <span
            class="ja50-ce-given-name">AL</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bennett</span> <span class="ja50-ce-given-name">S</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Adrenal steroidogenesis after B lymphocyte depletion therapy in new—onset Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2012</span>; <span class="ja50-sb-volume-nr">97</span>: </span><span
                class="ja50-sb-pages">E1927-E1932</span>. </span></div>
    <div class="refshow" id="bib56"><a class="back-bib" href="#back-bib56">56</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Vouillarmet</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Buron</span> <span
            class="ja50-ce-given-name">F</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Houzard</span> <span class="ja50-ce-given-name">C</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The first simultaneous kidney—adrenal gland—pancreas transplantation: outcome at 1 year</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Am J Transplant</span></span> <span class="ja50-sb-date">2013</span>; <span
                class="ja50-sb-volume-nr">13</span>: </span><span
                class="ja50-sb-pages">1905-1909</span>. </span></div>
    <div class="refshow" id="bib57"><a class="back-bib" href="#back-bib57">57</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Gan</span> <span
            class="ja50-ce-given-name">EH</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Macarthur</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mitchell</span> <span
            class="ja50-ce-given-name">AL</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Residual adrenal function in autoimmune addison's disease: improvement after tetracosactide (ACTH1—24) treatment</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2014</span>; <span class="ja50-sb-volume-nr">99</span>: </span><span
                class="ja50-sb-pages">111-118</span>. </span></div>
    <div class="refshow" id="bib58"><a class="back-bib" href="#back-bib58">58</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">White</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Adrenal crisis in treated Addison's disease: a predictable but under-managed event</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">162</span>: </span><span
                class="ja50-sb-pages">115-120</span>. </span></div>
    <div class="refshow" id="bib59"><a class="back-bib" href="#back-bib59">59</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hahner</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Loeffler</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bleicken</span> <span class="ja50-ce-given-name">B</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">162</span>: </span><span
                class="ja50-sb-pages">597-602</span>. </span></div>
    <div class="refshow" id="bib60"><a class="back-bib" href="#back-bib60">60</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Wass</span> <span
            class="ja50-ce-given-name">JA</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">How to avoid precipitating an acute adrenal crisis</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">BMJ</span></span> <span class="ja50-sb-date">2012</span>; <span
                class="ja50-sb-volume-nr">345</span>: </span><span
                class="ja50-sb-pages">e6333</span>. </span></div>
    <div class="refshow" id="bib61"><a class="back-bib" href="#back-bib61">61</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hahner</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Burger-Stritt</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Allolio</span> <span class="ja50-ce-given-name">B</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2013</span>; <span
                class="ja50-sb-volume-nr">169</span>: </span><span
                class="ja50-sb-pages">147-154</span>. </span></div>
    <div class="refshow" id="bib62"><a class="back-bib" href="#back-bib62">62</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Newrick</span> <span
            class="ja50-ce-given-name">PG</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Braatvedt</span> <span
            class="ja50-ce-given-name">G</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hancock</span> <span
            class="ja50-ce-given-name">J</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Corrall</span> <span class="ja50-ce-given-name">RJ</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Self-management of adrenal insufficiency by rectal hydrocortisone</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Lancet</span></span> <span
                class="ja50-sb-date">1990</span>; <span
                class="ja50-sb-volume-nr">335</span>: </span><span
                class="ja50-sb-pages">212-213</span>. </span></div>
    <div class="refshow" id="bib63"><a class="back-bib" href="#back-bib63">63</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Erichsen</span> <span
            class="ja50-ce-given-name">MM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Husebye</span> <span
            class="ja50-ce-given-name">ES</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Michelsen</span> <span
            class="ja50-ce-given-name">TM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Dahl</span> <span
            class="ja50-ce-given-name">AA</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span
            class="ja50-ce-given-name">K</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Sexuality and fertility in women with Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2010</span>; <span class="ja50-sb-volume-nr">95</span>: </span><span
                class="ja50-sb-pages">4354-4360</span>. </span></div>
    <div class="refshow" id="bib64"><a class="back-bib" href="#back-bib64">64</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bjornsdottir</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Cnattingius</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Brandt</span> <span class="ja50-ce-given-name">L</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Addison's disease in women is a risk factor for an adverse pregnancy outcome</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2010</span>; <span class="ja50-sb-volume-nr">95</span>: </span><span
                class="ja50-sb-pages">5249-5257</span>. </span></div>
    <div class="refshow" id="bib65"><a class="back-bib" href="#back-bib65">65</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Jung</span> <span
            class="ja50-ce-given-name">C</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ho</span> <span
            class="ja50-ce-given-name">JT</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Torpy</span> <span class="ja50-ce-given-name">DJ</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2011</span>; <span class="ja50-sb-volume-nr">96</span>: </span><span
                class="ja50-sb-pages">1533-1540</span>. </span></div>
    <div class="refshow" id="bib66"><a class="back-bib" href="#back-bib66">66</a> Demey-Ponsart E,
        Foidart J, Sulon J, Sodoyez J. Serum CBG, free and total cortisol and circadian patterns of
        adrenal function in normal pregnancy. <i>J Steroid Biochem</i> 982; <strong>16:</strong>
        165—69.
    </div>
    <div class="refshow" id="bib67"><a class="back-bib" href="#back-bib67">67</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mastorakos</span> <span
            class="ja50-ce-given-name">G</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ilias</span> <span
            class="ja50-ce-given-name">I</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Maternal and fetal hypothalamic—pituitary—adrenal axes during pregnancy and postpartum</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Ann N Y Acad Sci</span></span> <span class="ja50-sb-date">2003</span>; <span
                class="ja50-sb-volume-nr">997</span>: </span><span
                class="ja50-sb-pages">136-149</span>. </span></div>
    <div class="refshow" id="bib68"><a class="back-bib" href="#back-bib68">68</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lebbe</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Arlt</span> <span
            class="ja50-ce-given-name">W</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy?</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2013</span>; <span class="ja50-sb-volume-nr">78</span>: </span><span
                class="ja50-sb-pages">497-502</span>. </span></div>
    <div class="refshow" id="bib69"><a class="back-bib" href="#back-bib69">69</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Zelissen</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Croughs</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">van Rijk</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Raymakers</span> <span
            class="ja50-ce-given-name">J</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Ann Intern Med</span></span> <span class="ja50-sb-date">1994</span>; <span
                class="ja50-sb-volume-nr">120</span>: </span><span
                class="ja50-sb-pages">207-210</span>. </span></div>
    <div class="refshow" id="bib70"><a class="back-bib" href="#back-bib70">70</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Oelkers</span> <span
            class="ja50-ce-given-name">W</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Diederich</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bahr</span> <span
            class="ja50-ce-given-name">V</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Therapeutic strategies in adrenal insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Ann Endocrinol</span></span> <span class="ja50-sb-date">2001</span>; <span
                class="ja50-sb-volume-nr">62</span>: </span><span
                class="ja50-sb-pages">212-216</span>. </span></div>
    <div class="refshow" id="bib71"><a class="back-bib" href="#back-bib71">71</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Hahner</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Loeffler</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Fassnacht</span> <span
            class="ja50-ce-given-name">M</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross—sectional analysis</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2007</span>; <span class="ja50-sb-volume-nr">92</span>: </span><span
                class="ja50-sb-pages">3912-3922</span>. </span></div>
    <div class="refshow" id="bib72"><a class="back-bib" href="#back-bib72">72</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lightman</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Conway-Campbell</span> <span class="ja50-ce-given-name">B</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Nat Rev Neurosci</span></span> <span class="ja50-sb-date">2010</span>; <span
                class="ja50-sb-volume-nr">11</span>: </span><span
                class="ja50-sb-pages">710-718</span>. </span></div>
    <div class="refshow" id="bib73"><a class="back-bib" href="#back-bib73">73</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Stavreva</span> <span
            class="ja50-ce-given-name">D</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Wiench</span> <span class="ja50-ce-given-name">M</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">John</span> <span
            class="ja50-ce-given-name">S</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Nat Cell Biol</span></span> <span class="ja50-sb-date">2009</span>; <span
                class="ja50-sb-volume-nr">11</span>: </span><span
                class="ja50-sb-pages">1093-1102</span>. </span></div>
    <div class="refshow" id="bib74"><a class="back-bib" href="#back-bib74">74</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Benson</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Neumann</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Unger</span> <span class="ja50-ce-given-name">N</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2012</span>; <span
                class="ja50-sb-volume-nr">167</span>: </span><span
                class="ja50-sb-pages">679-685</span>. </span></div>
    <div class="refshow" id="bib75"><a class="back-bib" href="#back-bib75">75</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Husebye</span> <span class="ja50-ce-given-name">ES</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Continuous subcutaneous hydrocortisone infusion in Addison's disease</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2007</span>; <span
                class="ja50-sb-volume-nr">157</span>: </span><span
                class="ja50-sb-pages">109-112</span>. </span></div>
    <div class="refshow" id="bib76"><a class="back-bib" href="#back-bib76">76</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Erichsen</span> <span
            class="ja50-ce-given-name">MM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Lovas</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Fougner</span> <span class="ja50-ce-given-name">KJ</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Eur J Endocrinol</span></span> <span class="ja50-sb-date">2009</span>; <span
                class="ja50-sb-volume-nr">160</span>: </span><span
                class="ja50-sb-pages">233-237</span>. </span></div>
    <div class="refshow" id="bib77"><a class="back-bib" href="#back-bib77">77</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bensing</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Brandt</span> <span class="ja50-ce-given-name">L</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Tabaroj</span> <span
            class="ja50-ce-given-name">F</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">Clin Endocrinol (Oxf)</span></span> <span
                class="ja50-sb-date">2008</span>; <span class="ja50-sb-volume-nr">69</span>: </span><span
                class="ja50-sb-pages">697-704</span>. </span></div>
    <div class="refshow" id="bib78"><a class="back-bib" href="#back-bib78">78</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bergthorsdottir</span> <span class="ja50-ce-given-name">R</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Leonsson-Zachrisson</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Oden</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Johannsson</span> <span
            class="ja50-ce-given-name">G</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Premature mortality in patients with Addison's disease: a population-based study</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">4849-4853</span>. </span></div>
    <div class="refshow" id="bib79"><a class="back-bib" href="#back-bib79">79</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Burman</span> <span class="ja50-ce-given-name">P</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Mattsson</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Johannsson</span> <span
            class="ja50-ce-given-name">G</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Deaths among adult patients with hypopituitairism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2013</span>; <span class="ja50-sb-volume-nr">98</span>: </span><span
                class="ja50-sb-pages">1466-1475</span>. </span></div>
    <div class="refshow" id="bib80"><a class="back-bib" href="#back-bib80">80</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kraan</span> <span class="ja50-ce-given-name">GP</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Dullaart</span> <span
            class="ja50-ce-given-name">RP</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Pratt</span> <span class="ja50-ce-given-name">JJ</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Wolthers</span> <span
            class="ja50-ce-given-name">BG</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Drayer</span> <span
            class="ja50-ce-given-name">NM</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">De Bruin</span> <span class="ja50-ce-given-name">R</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">1998</span>; <span class="ja50-sb-volume-nr">83</span>: </span><span
                class="ja50-sb-pages">1247-1252</span>. </span></div>
    <div class="refshow" id="bib81"><a class="back-bib" href="#back-bib81">81</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Zueger</span> <span class="ja50-ce-given-name">T</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Kirchner</span> <span
            class="ja50-ce-given-name">P</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Herren</span> <span class="ja50-ce-given-name">C</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2012</span>; <span class="ja50-sb-volume-nr">97</span>: </span><span
                class="ja50-sb-pages">E1938-E1942</span>. </span></div>
    <div class="refshow" id="bib82"><a class="back-bib" href="#back-bib82">82</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Filipsson</span> <span
            class="ja50-ce-given-name">H</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Monson</span> <span class="ja50-ce-given-name">J</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Koltowska-Haggstrom</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Mattsson</span> <span
            class="ja50-ce-given-name">A</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Johannsson</span> <span
            class="ja50-ce-given-name">G</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">The impact ofglucocorticoid replacement regimenson metabolic outcome and comorbidity in hypopituitary patients</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">2006</span>; <span class="ja50-sb-volume-nr">91</span>: </span><span
                class="ja50-sb-pages">3954-3961</span>. </span></div>
    <div class="refshow" id="bib83"><a class="back-bib" href="#back-bib83">83</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Giordano</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Marzotti</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Balbo</span> <span class="ja50-ce-given-name">M</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Endocrinol Invest</span></span> <span
                class="ja50-sb-date">2009</span>; <span class="ja50-sb-volume-nr">32</span>: </span><span
                class="ja50-sb-pages">917-923</span>. </span></div>
    <div class="refshow" id="bib84"><a class="back-bib" href="#back-bib84">84</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Plat</span> <span
            class="ja50-ce-given-name">L</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Leproult</span> <span
            class="ja50-ce-given-name">R</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">L'Hermite-Baleriaux</span> <span
            class="ja50-ce-given-name">M</span></span>, et al</span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Clin Endocrinol Metab</span></span> <span
                class="ja50-sb-date">1999</span>; <span class="ja50-sb-volume-nr">84</span>: </span><span
                class="ja50-sb-pages">3082-3092</span>. </span></div>
    <div class="refshow" id="bib85"><a class="back-bib" href="#back-bib85">85</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bjornsdottir</span> <span class="ja50-ce-given-name">S</span>, </span><span
            class="ja50-sb-author"><span class="ja50-ce-surname">Saaf</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Bensing</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Kampe</span> <span
            class="ja50-ce-given-name">O</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Michaelsson</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ludvigsson</span> <span
            class="ja50-ce-given-name">J</span></span></span>. <span class="ja50-sb-title"><span
            class="ja50-sb-maintitle">Risk of hip fracture in Addison's disease: a population-based cohort study</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">J Intern Med</span></span> <span
                class="ja50-sb-date">2011</span>; <span
                class="ja50-sb-volume-nr">270</span>: </span><span
                class="ja50-sb-pages">187-195</span>. </span></div>
    <div class="refshow" id="bib86"><a class="back-bib" href="#back-bib86">86</a> <span
            class="ja50-sb-contribution"><span class="ja50-sb-authors"><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Koetz</span> <span
            class="ja50-ce-given-name">K</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Ventz</span> <span
            class="ja50-ce-given-name">M</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Diederich</span> <span
            class="ja50-ce-given-name">S</span>, </span><span class="ja50-sb-author"><span
            class="ja50-ce-surname">Quinkler</span> <span class="ja50-ce-given-name">M</span></span></span>. <span
            class="ja50-sb-title"><span class="ja50-sb-maintitle">Bone mineral density is not significantly reduced in adult patients onlow-dose glucocorticoid replacement therapy</span></span></span>.
        <span class="ja50-sb-host"><span class="ja50-sb-issue"><span class="ja50-sb-title"><span
                class="ja50-sb-maintitle">JCEM</span></span> <span class="ja50-sb-date">2012</span>; <span
                class="ja50-sb-volume-nr">97</span>: </span><span class="ja50-sb-pages">85-92</span>. </span>
    </div>
</div>
<div class="bibMultiContainer" id="bibMultiContainer">
    <div id="bibMulti2" class="ref1"></div>
</div>
<div id="front-matter" class="fm">
    ©
    2015 Elsevier Ltd. All rights reserved.<br/>S2213-8587(14)70142-1 - see front matter <br/>DOI:
    10.1016/S2213-8587(14)70142-1
</div>
<script src="../../js/style.js" type="text/javascript"></script>
<script src="../../../notes_js/custom.js"></script>
</body>
</html>
